

Structure-kinetic-relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2

Benedict-Tilman Berger^{1, 9, *}, Marta Amaral^{2, 3, 5, *}, Daria B. Kokh^{4*}, Ariane Nunes-Alves^{4,7}, Djordje Musil², Timo Heinrich², Martin Schröder^{1, 9}, Rebecca Neil⁴, Jing Wang⁵, Iva Navratilova⁶, Joerg Bomke², Jonathan M. Elkins⁵, Susanne Müller^{1,9}, Matthias Frech², Rebecca C. Wade^{4, 7, 8} and Stefan Knapp^{1,9,10 #}

¹Structural Genomics Consortium, Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences, Max-von-Laue-Straße 15, 60438 Frankfurt am Main, Germany

²Discovery Technologies, Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany

³Instituto de Biologia Experimental e Tecnológica, Avenida da República, Estação Agronómica Nacional, 2780-157 Oeiras, Portugal

⁴Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Schloß-Wolfsbrunnenweg 35, 69118 Heidelberg, Germany

⁵Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.

⁶Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK

⁷Zentrum für Molekulare Biologie der Universität Heidelberg, DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

⁸Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Im Neuenheimer Feld 205, 69120 Heidelberg, Germany

⁹Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences, Max-von-Laue-Straße 9, 60438 Frankfurt am Main, Germany

¹⁰German Cancer network DKTK and Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt am Main, Germany

*Authors contributed equally

§ current address: Biologics Research, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main, Germany

#Lead contact and Author for correspondence: knapp@pharmchem.uni-frankfurt.de

Keywords: Focal Adhesion Kinase (FAK), Proline-rich Tyrosine Kinase 2 (PYK2), ligand residence time, NanoBRET, kinase inhibitor, τ RAMD

Summary

There is increasing evidence of a significant correlation between prolonged drug-target residence time and increased drug efficacy. Here, we report a structural rationale for kinetic selectivity between two closely related kinases: Focal Adhesion Kinase (FAK) and Proline-rich Tyrosine Kinase 2 (PYK2). We found that slow off-rate FAK inhibitors induce helical structure at the DFG motif of FAK but not PYK2. Binding kinetic data, high resolution structures and mutagenesis data support the role of hydrophobic interactions of inhibitors with the DFG helical region providing a structural rationale for slow dissociation rates from FAK and kinetic selectivity over PYK2. Our experimental data correlated well with computed relative residence times from molecular simulations providing a feasible strategy for rationally optimizing ligand residence times. We suggest that the interplay between the protein structural mobility and ligand-induced effects is a key regulator of the kinetic selectivity of inhibitors of FAK versus PYK2.

Introduction

Focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) are two closely related non-receptor tyrosine kinases that constitute the subfamily of adhesion kinases (Schlaepfer et al., 1999). Both kinases are involved in the regulation of cell migration, adhesion and survival in response to extracellular signals and they share a similar multidomain organization comprising an N-terminal FERM domain, a central catalytic kinase domain (with 61% sequence identity), a proline rich (PR) region and a C-terminal focal adhesion targeting (FAT) domain (Lipinski and Loftus, 2010). Despite their homology, signaling events leading to kinase activation differ, with FAK being primarily activated by integrins, growth factor receptors, and cytokine receptors, while PYK2 activation is dependent on intracellular calcium mobilization (Avraham et al., 2000). Focal adhesion kinases promote tumor proliferation and metastasis and that they are overexpressed and upregulated in several types of cancers (Fan and Guan, 2011; Tai et al., 2015; Wendt et al., 2013). PYK2 has been found to be upregulated when FAK activity is suppressed, suggesting compensatory signaling pathways that may result in drug resistance. Efforts have therefore been made to develop dual FAK/PYK2 inhibitors that are currently in clinical testing (Lv et al., 2018).

An interesting series of aminopyrimidines was reported by Pfizer, resulting in the development of dual FAK/PYK2 inhibitors PF-562271 (**1**) (Roberts et al., 2008), PF-431396 (Buckbinder et al., 2007) and defactinib (PF-8554878 (Jones et al., 2011)), as well as selective FAK (PF-573228 (Slack-Davis et al., 2007)) and PYK2 (PF-719 (Tse et al., 2012)) inhibitors, respectively. Despite the high sequence similarity of the kinase domains of FAK and PYK2 (**Fig. S1**), **1** adopts different back pocket binding modes in the two proteins (**Fig. 1A**). Strikingly, the conserved tripeptide DFG-motif forms an alpha-helical structure in FAK enabling multiple contacts between inhibitor and kinase, notably between the pyridine ring and L567 (**Fig. 1B**). In PYK2, the same amino acid residues are positioned in a linear conformation with only PYK2-D567 being able to form contacts with the inhibitor (**Fig. 1C**). This helical conformation of the DFG-motif in FAK has been invoked as providing a possible structural explanation for the approximately 9-fold greater potency of **1** for FAK ($IC_{50} = 1.5$ nM) over PYK2 ($IC_{50} = 13$ nM) (Roberts et al., 2008).

Recently, several studies have suggested that the kinetic properties of a drug, specifically the residence time ($\tau = 1/k_{off}$), may provide a better indication of the duration of the pharmacodynamic action *in vivo* than binding affinity alone (Copeland, 2016; Schuetz et al., 2017). The observation of a helical conformation in FAK but not PYK2 suggests that it may provide a mechanism for the kinetic selectivity of **1**. The structurally very similar dual FAK/PYK2 inhibitor PF-431396 (**10** – with phenylsulfonamide instead of the aminopyridine in **1**) shows a similar selectivity in potency (FAK $IC_{50} = 1.5$ nM over PYK2 $IC_{50} = 11$ nM)

1
2
3
4 (Roberts et al., 2008). As **10** was also reported to show fast binding kinetics on PYK2 ($k_{on} > 10^6 \text{ M}^{-1}\text{s}^{-1}$, $k_{off} >$
5 10^{-2} s^{-1}) (Han et al., 2009), we hypothesize that the about 7-fold selectivity for FAK - and therefore as well
6 the about 9-fold selectivity (Roberts et al., 2008) of **1** - may be related to very slow binding kinetics to FAK.
7
8 As selectivity is often hard to achieve for related protein kinases, an understanding of the mechanisms of
9 kinetic selectivity of inhibitors of FAK and PYK2 would be beneficial for future medicinal chemistry efforts.
10
11 Therefore, in this study, we explored the structural features that modulate the kinetic properties of a series
12 of FAK and PYK2 inhibitors to support the development of kinetically selective or balanced dual FAK/PYK
13 inhibitors. In order to gain a mechanistic understanding of the distinct kinetic profiles of FAK and PYK2
14 binding, we performed surface plasmon resonance assays, binding experiments in cells, structural and site-
15 directed mutagenesis studies, conventional molecular dynamics (MD) and τ random acceleration
16 molecular dynamics (τ RAMD) simulations. This combination of techniques allowed us to relate the
17 structural and dynamic differences between the two kinases to the kinetic selectivity of the inhibitors.
18
19
20
21
22
23
24
25
26

27 Results and Discussion

30 Design of a series of inhibitors to probe the structure activity relationship in FAK and PYK2

31
32 Based on the comparison of the crystal structures of **1** in complex with FAK and PYK2 (**Fig. 1**), we designed
33 and synthesized a series of inhibitors to probe the influence of interactions with different parts of the ATP
34 binding site on binding kinetics in FAK and PYK2. The central amino-pyrimidine hinge binding scaffold was
35 modified at three positions, probing interactions with the solvent exposed pocket and interactions with
36 the non-conserved upper lobe residues (**R¹**), the DFG helix induced in FAK after ligand binding (**R²**), as well
37 as the back pocket interface with the induced helix in FAK (**R³**)
38
39
40
41
42

43 **Table 1**). For a first assessment of the effect of the modifications on inhibitor binding kinetics and affinity,
44 we performed surface plasmon resonance (SPR) measurements.
45
46

47 In order to develop inhibitors that show different binding kinetics between these two related kinases, we
48 were particularly interested in the role of the hydrophobic interaction of the inhibitor with the induced
49 helix located C-terminal to the FAK DFG motif (residues D564-G566) which positioned FAK-L567 into the
50 ATP binding site. The pyridyl-methansulfonamide in **R¹** was therefore replaced by diverse aromatic
51 moieties (compounds **5-12**) modulating the electron density of the pendant aromatic ring system, as well
52 as substitution patterns in the ring.
53
54
55
56
57

58 Another interaction unique to FAK was a polar contact of the oxindole of **1** with FAK-R426. Despite
59 conservation of this residue in PYK2 (R429), this interaction was not observed in crystal structures of this
60
61
62
63
64
65

1
2
3
4 kinase. To probe the contribution of this structural difference on binding kinetics, we introduced single
5 aromatic ring systems instead of the oxindole moiety in **1**, including a phenyl moiety (**3**), a ring expanded
6 3,4 dihydroquinoline-2-one (**4** and **5**), N-methylbenzamide (**11**, defactinib) and N-
7 methylbenzenesulfonamide (**12**). While we did not obtain data for a substitution of the oxindole in R^1 with
8 dihydroquinoline-2-one in **4** we observed a comparable potency to **1** by introducing a
9 methylsulfonylbenzene in R^1 (**5**). In position R^3 , only a $-CF_3$ group and a CF_3 -deleted variant (-H, **2**) were
10 tested. The removal of the trifluoromethyl group in **2** resulted in a significant reduction of affinity
11 compared to PF-562271 (**1**), associated with shorter residence time as expected for the key interaction of
12 the trifluoromethyl group with the back pocket. The trifluoromethyl group was therefore kept in all other
13 inhibitors that we investigated.
14
15
16
17
18
19
20
21
22
23

24 L567-ligand interactions increased potency and prolonged residence times in FAK

25 Modifications in the selected inhibitor set, significantly modulated binding affinity for FAK and PYK2.
26 Interestingly, introducing a phenylsulfonamide moiety at position R^1 in **10** resulted in a 4-fold
27 improvement in potency for FAK compared to the parent compound **1**. We hypothesized that the benzene
28 ring of **10** provided a more favorable hydrophobic interaction with L567 compared to the pyridine ring in
29 **1**. Indeed, if the polarity of the ring system was increased by incorporation of two nitrogen atoms as
30 exemplified in **11**, the affinity decreased further. The corresponding change in off-rate was a result of a
31 difference in binding free energy, as the on-rates of **1**, **10** and **11** were similar. For PYK2, we observed
32 similar affinities and kinetic parameters for **1**, **10**, and **11**, in agreement with the lack of the induced helical
33 structure and interaction with the conserved PYK2-L570.
34
35
36
37
38
39
40
41

42 The introduction of a sulfonylphenyl moiety at R^1 (**5**) resulted in a decreased affinity for FAK. This
43 modification was accompanied by a 2-fold increase in the inhibitor off-rate. Compared to **1**, the removal
44 of the sulfonamide in **8** led to a decrease in binding affinity and interestingly, a substitution of the pyridine
45 ring in **8** with benzene (**9**) or para-fluorobenzene (**7**) was not tolerated and resulted in an affinity loss of
46 350-fold and 1300-fold, respectively. Introduction of an indoline-2-one ring system was however tolerated
47 (**6**) maintaining low nanomolar affinity. Similar effects on inhibitor binding affinity by R^1 substitutions were
48 observed for PYK2.
49
50
51
52
53
54

55 Interestingly, the R^2 substituent played a key role in determining both potency and the binding kinetics
56 profile. Changing the oxindole ring in **1** to a phenyl (**3**) resulted in a 93-fold decrease in potency and a 60-
57 fold drop in the on-rate, most likely because the phenyl ring does not allow the formation of a hydrogen
58
59
60
61
62
63
64
65

1
2
3
4 bond with FAK-R426. Inhibitor **12** has been reported as a PYK2 selective inhibitor (Tse et al., 2012) and we
5 indeed measured tighter binding to PYK2 but observed only about 6-fold selectivity against FAK.
6

7
8 Comparing the selectivity profiles of both FAK and PYK2, it was intriguing that the k_{on} - k_{off} -plot (**Fig. S3**)
9 clearly demonstrated that most inhibitors had very similar association rate constants k_{on} . Remarkably, the
10 variation was less than 10-fold over all inhibitors tested. As a result, the different binding affinities for
11 these two kinases were mainly due to differences in the dissociation rate constant k_{off} . Interestingly,
12 despite similar IC_{50} values, we observed that **10** showed a dissociation rate from FAK of 138 min - more
13 than two orders of magnitude slower than that reported for PYK2 (Han et al., 2009).
14
15
16
17
18

19 **Slow off-rate inhibitors induce a helical conformation of the activation loop in FAK**

20
21 In order to better understand the structural mechanisms giving rise to the different binding kinetics of this
22 inhibitor series, we solved six crystal structures of FAK in complex with different aminopyrimidine
23 derivatives, including the most interesting substitutions in **R¹**, **R²** and **R³** (**Fig. 2**).
24
25
26
27
28

29
30 The structure of the inhibitor with the slowest dissociation off-rate – **10** – in complex with FAK confirmed
31 the overall binding mode previously described for **1** (Roberts et al., 2008). **10** formed hydrogen-bonds
32 between the inhibitor and the backbone of C502 located in the hinge region. The oxygen atom of the
33 amino-oxindole (**R²**) was within hydrogen-bonding distance of the side chain of R426. The trifluoromethyl
34 group (**R³**) bound to the cavity created by the sidechains of M499, D564 and L567. The phenyl-sulfonamide
35 (**R¹**) formed a hydrophobic interaction with L567. Finally, the sulfonamide was stabilized by a hydrogen
36 bond with the backbone amide of FAK-D564. The conformation of this helix and the binding mode of the
37 inhibitor series discussed here were similar to that reported in the structure of the complex with the
38 clinical FAK inhibitor TAE226 (**Fig. S2**) (Lietha and Eck, 2008).
39
40
41
42
43
44
45

46 In addition, we also determined structures in complex with **3** and **5**, harboring a sulfonamide moiety in **R¹**.
47 Intriguingly, all structures with these slow off-rate inhibitors revealed an induced helical structure in the
48 activation loop region. The structure in complex with **4** induced a helical conformation in FAK. Therefore,
49 we assumed similar kinetics compared to **1**. Interestingly, for **5**, the FAK-L567 interaction was mainly due
50 to a 180° rotated T-shaped π -stacking interaction of the aromatic ring system based on the shorter
51 distance provided by the phenylsulfodioxide without the additional atoms present in **1** and additionally
52 formed a hydrophobic interaction with L553.
53
54
55
56
57
58

59 We observed that the absence of the **R¹** methyl sulfonamide group in **8** prevented the formation of the
60 DFG-motif helix and this inhibitor was shown to have an increased off-rate compared to **1**. The oxindole
61
62
63
64
65

1
2
3
4 ring of **1** and **10** in position **R**² interacted with FAK R426 via a hydrogen bond. Changes in the **R**² position
5
6 did not lead to different interactions of the **R**² groups. However, while the oxindole moiety was within
7
8 hydrogen bonding distance of FAK R426, this interaction appeared transient and was not present in all
9
10 chains in the asymmetric unit. This makes an involvement in the modulation of the inhibitors' on-rate less
11
12 likely. We were successful in solving the structure of an inhibitor harbouring different moieties in **R**³, which
13
14 pointed towards the back pocket. Analysis of **2** in complex with FAK revealed significant differences in the
15
16 pyridyl-methansulfonamide group orientation when compared to **10** and **1**, which in the case of **2** did not
17
18 allow a direct interaction with the DFG-motif. Hence, its conformation was the canonical DFG-in
19
20 arrangement. The trifluoromethyl group was involved in hydrophobic interactions with M499, D564, and
21
22 L567 in the structures of inhibitors **1** and **3-11**. The lack of these hydrophobic interactions in **2** explained
23
24 the impact of this substituent on binding affinity and fast binding dissociation kinetics.

25
26 As expected from the SAR and SKR analysis, the slowest off-rate inhibitors of FAK, **5** and **10**, formed similar
27
28 interactions as reported for **1**. In particular, the DFG motif was stabilized in a helical conformation by
29
30 hydrophobic interactions with FAK L567. Simulations suggested that the very potent and slow off-rate
31
32 compound **11** had a similar binding mode to that one observed experimentally for **10** and **1**. All the
33
34 inhibitors contained a sulfoxide moiety coupled to an aromatic ring system in **R**¹. The overall results
35
36 revealed some general trends in inhibitor binding characteristics as a function of the structural
37
38 rearrangement of the DFG motif. Compounds that induce a helical conformation of the DFG motif via a
39
40 hydrophobic interaction with FAK-L567 had significantly slower binding kinetics and higher potency when
41
42 compared to compounds that assumed a type-I binding mode.

43 The kinetic selectivity profile of FAK and PYK2 is dictated by the formation of a helical 44 conformation of the DFG motif

45 We compared our structural data of FAK with published structures of PYK2 in complex with **1** (PDB 5tob)
46
47 (**Fig. 1**), **10** (PDB 3fzr, **Fig. 3A**) and **12** (PDB 3h3c, **Fig. 3B**) to identify crucial interaction residues that are
48
49 relevant for the kinetic selectivity for either FAK or PYK2.

50
51
52 The superimposed crystal structures of FAK and PYK2 in complex with **10** showed a similar conformation
53
54 of the amino-methyl-phenyl-sulfonamide group as that reported for **1**. In contrast to an interaction of **10**
55
56 with the helical DFG motif in FAK, this interaction is missing for PYK2. The interaction of **10** with PYK2 is
57
58 characterized by a DFG-out conformation and hydrophobic interactions with residues preceding the P-
59
60 loop (L431, G432) similar to FAK. We hypothesized that the differences between the conformations of the
61
62 DFG motif are likely to contribute to differences in potency and paralogue selectivity of the trifluoromethyl

1
2
3
4 pyrimidine series, as previously reported (Heinrich et al., 2013; Roberts et al., 2008). The superimposed
5
6 crystal structures of FAK and PYK2 also revealed a different conformation of the P-loop and a different
7
8 position of α C. Although this region did not directly interact with the inhibitor, the difference in one
9
10 particular amino acid residue of the P-loop region, F435 (PYK2) vs. Q432 (FAK) (**Fig. S1**), might impact the
11
12 stabilization of the helical conformation of the DFG-motif in FAK, as Q432 interacted with the backbone of
13
14 G566. While FAK-R426 showed an interaction with **10**, the corresponding arginine R429 in PYK2 was not
15
16 within hydrogen-bonding distance.

17
18 In contrast to **10**, which showed a 9-fold selectivity for FAK over PYK2, **12** shared the amino pyrimidine
19
20 scaffold, but harbored different moieties **R¹** and **R²** and has been reported as a PYK2-selective inhibitor
21
22 (Tse et al., 2012). We solved the crystal structure of **12** with FAK to provide structural insights into the
23
24 mechanism of this selectivity. Exchanging **R¹** and **R²** residues in contrast to **10**, resulted in a shift in the
25
26 position of the sulfonamide, which interacted with R426 (FAK) in β 1 in both kinases. An interaction of the
27
28 inhibitor with the conserved leucine residue L567 or the respective L570 in PYK2 was missing in both FAK
29
30 and PYK2 stabilizing a DFG-in conformation. The FAK DFG motif did not form the helical secondary
31
32 structure in complex with **12** - as seen for **10** - supporting the idea that differences in the arrangement of
33
34 the DFG motif were relevant for the inhibitor selectivity of **12** for PYK2.

35 36 **Protein flexibility and the dynamics of the protein-ligand interactions differ for FAK and PYK2**

37
38 To investigate the origin of the differences in the binding rates between FAK and PYK2 for the set of
39
40 compounds considered, we performed MD simulations. We carried out both conventional MD simulations
41
42 of the protein-ligand complexes and τ RAMD (Kokh et al., 2018) simulations of ligand dissociation for all 12
43
44 compounds binding FAK and for the 10 compounds whose binding to PYK2 was observed experimentally.
45
46 Conventional MD simulations of the protein-ligand complexes showed that the ligands and the parts of
47
48 the protein that line the binding site (in particular the β 1, α C, and DFG-motif regions) generally showed
49
50 more mobility in PYK2 than in FAK (**Fig. 4A**). The DFG-motif region was highly mobile for the complexes
51
52 with compounds **1** and **3** in PYK2 simulated starting from the crystal structure with PDB 5tob, where the
53
54 position of the phenylalanine of the DFG fragment is different from in other PYK2 crystal structures and
55
56 the side chain position was found to be more variable in MD simulations (for details, see **Fig. S4**).

57
58 To explore the possible reasons for the structural stability of FAK with respect to PYK2, we compared
59
60 protein-ligand interaction fingerprints in the MD trajectories. Although the pattern of protein-ligand
61
62 interactions in trajectories for PYK2 and FAK was generally similar (**Fig. 4B, C**), there were several
63
64 differences. First, with exception of compound **2**, an additional hydrogen bond with D564 appeared in the
65

1
2
3
4 FAK complexes with compounds that have a methane sulfonamide **R**¹ moiety oriented towards the DFG-
5 motif (see **Fig. 4D**).

6
7
8 The number and stability of protein-ligand hydrophobic interactions is larger in FAK. These interactions
9 included not only the DFG-motif (D564/D567,L569/570), having a helical conformation in FAK but also
10 interactions with residues V484 located deep in the pocket and L553 in addition to interactions with
11 conserved residues V436/V439 and A452/A455 (**Fig. 4D**). Additionally, the hinge residue L501 in FAK
12 formed a temporary contact with most ligands. This suggests a tighter packing of the ligand in the binding
13 pocket of FAK than PYK2. Indeed, most of the compounds bound to PYK2 form a water-mediated hydrogen
14 bond with D567 through the **R**¹ moiety, which indicates that the pocket is relatively open and partially
15 hydrophilic. For FAK, this interaction is observed only for **2** and **6** which bound to the helical DFG-loop
16 conformation. In agreement with our structural analysis, we did not observe stable hydrogen bonding to
17 FAK R426 from the oxygen in the oxindole ring and R426 was only transiently involved in a direct or water-
18 mediated hydrogen bond with ligands (**Fig. 4B**).

19
20
21
22
23
24
25
26
27
28 Next, we employed the τ RAMD procedure to simulate ligand unbinding and to evaluate the relative
29 residence times of the compounds studied. The computed τ RAMD residence times overall correlate well
30 with SPR data ($R^2= 0.91$ for the whole set of compounds, **Fig. 4E**), including those modelled by similarity or
31 docked (such as **6**, **7** and **11** for FAK, and most compounds for PYK2, see Methods). The compounds that
32 dissociate more slowly from FAK were well separated from those with faster dissociation rates. However,
33 the ranking of the fast dissociating compounds ($k_{\text{off}} > 0.03\text{s}^{-1}$) was less accurate which was potentially due
34 to the uncertainty in the structure of the modelled complex, as only a few crystal structures of PYK2 (**1**, **10**
35 and **12**) were available (see, for example, the results of simulations with different docking positions for
36 compounds **3** and **9** bound to PYK2 and FAK, respectively, **Fig. S4**).

37
38
39
40
41
42
43
44
45 All compounds with a sulfonamide moiety at **R**¹ bound to the FAK complex with a helical DFG-motif
46 conformation, formed hydrogen bonds with the DFG-motif backbone (residue D564, **Fig. 4D**), and showed
47 long residence times ($k_{\text{off}} < 0.01 \text{ s}^{-1}$). This interaction, along with the hydrophobic contact with L567,
48 seemed to be critical for residence time prolongation. Indeed, for two fast dissociating compounds, **7** and
49 **9** ($k_{\text{off}} > 0.05 \text{ s}^{-1}$), with aromatic **R**¹ substitutions, we did not observe differences in residence times when
50 the simulated ligands were docked into the protein structure with a helical or extended conformation of
51 the DFG-motif (see for example, simulation results for compound **9** for different conformations of the
52 protein binding site in **Fig. S4**). Importantly, both compounds formed a hydrophobic contact with L567 in
53 the helical DFG-loop structure, although it was much less stable than in the case of compounds with a
54 sulfonamide moiety at **R**¹. One more interesting feature was observed in the series of simulations for
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 compound **9**: the ligand docking positions for which a transient contact with R426 was possible were found
5
6 to dissociate several fold slower than those for which this hydrogen bond was not observed (see **Fig. S4**).
7
8 Thus, both protein structural differences (tighter pocket and more hydrophobic contacts in FAK) and the
9
10 ligand's ability to form additional hydrogen bonds appeared important for slow dissociation rates.

11 12 13 **Binding potency and kinetics of FAK and PYK2 in living cells**

14
15 In order to validate the *in vitro* selectivity and slow binding kinetics of the present series of compounds for
16
17 FAK versus PYK2, we assessed target engagement and binding kinetics in living cells under near
18
19 physiological conditions using the NanoBRET technology (Roberts et al., 2015). For the target engagement
20
21 assays, the apparent tracer affinity values of tracer K5 (Vasta et al., 2018) were determined (46 nM and
22
23 78 nM for FAK and PYK2, respectively) and used as input parameters in the assay setup for FAK and PYK2
24
25 (**Fig. S5**). Representative results of the target engagement assay for compounds **10** and **1** are shown in **Fig.**
26
27 **5A**. The intracellular apparent affinities (**6, 7**) were generally 10-times weaker than the binding affinities
28
29 calculated from the *in vitro* SPR measurements (**Fig. 5B**). NanoBRET data were in very good agreement
30
31 with previously reported IC_{50} values (Allen et al., 2009; Heinrich et al., 2013; Walker et al., 2008; Walker et
32
33 al., 2009) for both FAK and PYK2. FAK *in vitro* selectivity for the present series of compounds was translated
34
35 into the cellular context, where **5** was the most selective compound for FAK with a 330-fold difference
36
37 compared to PYK2.

38
39 Next, we investigated the kinetic aspects in the cellular context using the NanoBRET technology in a wash-
40
41 out format. The tracer used had the required rapid binding kinetics, making it suitable for the kinetic
42
43 analysis of slower-binding inhibitors (**Fig. S5**). After incubation of the individual inhibitors with their target
44
45 at a concentration of 10-fold of their respective IC_{50} to achieve 90% target occupancy, we removed the
46
47 unbound compound by wash-out and added the tracer whose association was monitored over time (**Fig.**
48
49 **S5, Table S3**). Our residence time analysis by NanoBRET revealed remarkably slow dissociation rates for
50
51 **10** on FAK compared to PYK2 and distinguishably slower kinetics for **1** on FAK. For PYK2, in agreement with
52
53 our SPR data, no inhibitors with slow off-rates were identified in cells. We confirmed that compounds **1**
54
55 and **10**, which had the longest residence times among the entire series of pyrimidines *in vitro*, also had
56
57 slow binding kinetics (**Fig. 5C**) in cells. As expected from the SPR data, compound **10** showed fast binding
58
59 kinetics for PYK2, providing an indication for kinetic selectivity. The observed rank-order of intracellular
60
61 residence times was in good agreement with the residence times determined in SPR experiments. It is
62
63 noteworthy that in the NanoBRET assay, compound **4** showed a very similar potency to compound **1** and
64
65

1
2
3
4 an even longer half-life of dissociation. Together with the relative residence time computations (**Fig. 4E**),
5 these data indicate a similar kinetic behavior of **4** compared to **1**.
6

7
8 Interestingly, although **5** had a higher selectivity for FAK over PYK2, **10** showed longer occupancy due to
9 its slow dissociation kinetics, providing evidence that the residence time can be a valuable indicator of
10 target occupancy.
11
12
13

14 15 **Structural mechanisms affecting the protein binding site flexibility in FAK and PYK2**

16
17 Analysis of the crystal structures and the protein-ligand interaction contacts in MD simulations suggests
18 that the protein structure with a helical DFG-motif conformation formed a tighter binding pocket and
19 enabled a larger number of hydrophobic contacts between the protein and the ligand relative to that with
20 a loop DFG-motif conformation. This analysis did not explain why PYK2 was unable to adopt the helical
21 DFG-motif conformation to form complexes with higher affinity. A possible explanation for such structural
22 differences are sequence variations between FAK and PYK2 (**Fig. S1**), which may cause differences in
23 protein flexibility. The DFG-motif and several of the following residues are conserved in PYK2 and FAK,
24 whereas in other regions of the binding site, in particular in β 1 and the hinge region, some sequence
25 variations might affect domain plasticity.
26
27
28
29
30
31
32

33
34 The most notable specific interaction observed in the crystal structures of FAK was a hydrogen bond
35 between the sidechain amide nitrogen of Q432, located in the P-loop, and the backbone oxygen atom of
36 L567, located next to the helical DFG motif (**Fig. 6A**). This interaction is not possible in PYK2 because the
37 hydrophobic F435 is at the Q432 position (**Fig. 6B**), although a hydrophobic residue at this position is
38 unusual among the non-receptor kinases (**Fig. S6**). To explore whether a residue corresponding to Q432 in
39 FAK could stabilize the PYK2 protein structure, we compared MD simulations of the apo wild-type PYK2
40 with F435Q and F435A mutants. Although the PYK2 mutation F435Q was slightly more stable (**Fig. S6**),
41 neither coiling of the DFG-motif loop nor contact between Q435 and the DFG-motif region were observed
42 in the MD trajectories, most likely because this would require a much longer simulation time. We also did
43 not observe any stable aromatic stacking of F435 with the surrounding aromatic residues in PYK2, which
44 might affect the position of the P-loop in PYK2, although the Q and A residues at position 435 were slightly
45 less stable (**Fig. S6**). Thus, the simulations of single-point mutants of PYK2 did not provide clear indicators
46 of differences in the structural behaviour of FAK and PYK2.
47
48
49
50
51
52
53
54
55
56

57
58 We next investigated whether the helix-like conformation of the DFG-motif region would be unfavourable
59 in apo-PYK2. For this purpose, we built a “chimeric” PYK2 structure with the helical DFG motif region
60
61
62
63
64
65

1
2
3
4 mirroring the one observed in FAK complexes with slowly dissociating compounds (see Methods section).
5
6 Then, we performed a series of MD simulations ($\sim 1 \mu\text{s}$ in total) for FAK and PYK2 (both with the helical
7
8 DFG-motif). The RMSD of all structural elements (the helical DFG-motif, $\beta 1$, and αC) of the binding site was
9
10 quite low in the unbound FAK ($< 2 \text{\AA}$, **Fig. S6**), which indicated that the DFG-helical form in FAK was relatively
11
12 stable even in the absence of a ligand. Surprisingly, the hydrogen-bond between G566 and Q432 was not
13
14 preserved and appeared on average in only half of the frames (**Fig. 6E**). Thus, the presence of Q432 in FAK
15
16 instead of F435 in PYK2 - while important - may not be the only factor that determines the DFG-motif
17
18 conformation.

19
20 In contrast to FAK, the binding site in the “chimeric” structure of PYK2 was flexible and underwent
21
22 considerable reconstruction (backbone RMSD of about 3\AA for the helical segment containing the DFG-
23
24 motif, **Fig. S6**). Specifically, the αC moved away from the ATP binding pocket towards a position similar to
25
26 that in the FAK structure (**Fig. S6**) and $\beta 1$ slightly changed its conformation. However, its first strand did
27
28 not adopt the conformation observed in FAK, i.e. distorted in the middle (PYK2 and FAK are compared in
29
30 **Fig. 6C**). Instead, it preserved the well-defined β -sheet structure of the original PYK2 conformation. As
31
32 mentioned above, the difference in the β -sheet structure in PYK2 and FAK is likely caused by two residues:
33
34 G425 and C427 in FAK are replaced by larger residues, N428 and I430 in PYK2, respectively. As a result, in
35
36 the “chimeric” PYK2 structure, $\beta 1$ and the following P-loop were shifted towards the helix of the DFG-
37
38 motif and the following A-loop region by about 4\AA . This shift led to the repositioning of L570 as shown
39
40 in **Fig. 6C**, where FAK bound to compound **1** is compared with the “chimeric” PYK2 structure after about
41
42 200 ns of equilibration. Finally, hydrogen-bonds between the helical DFG-motif fragment and the rest of
43
44 the protein were different in “chimeric” PYK2 relative to FAK. Apart from the missing interaction with G569
45
46 (hydrogen-bond between G566 and R432 in FAK), the interactions of S571 and D572 were also less stable
47
48 in PYK2 (**Fig. 6E**). All these results clearly indicate that, even with the same helical DFG-motif, the apo-
49
50 structure and stability of the binding site in PYK2 differs from FAK.

51
52 To assess the effect of the helical conformation of the DFG-motif loop on the ligand unbinding rate, we
53
54 modelled compound **3** bound to the “chimeric” PYK2 structure in the same pose as in FAK (PDB 3bz3; **Fig.**
55
56 **S6**, structures 3 and 4) and computed its residence time. The computed residence time of compound **3**
57
58 was doubled relative to that for the loop DFG-motif conformation (see point denoted by “(3)” in **Fig.4E**)
59
60 but it was still ~ 5 -fold shorter than for the same compound bound to FAK. The difference between the
61
62 protein-ligand interaction fingerprints of FAK and PYK2 is shown in **Fig. 6D**. Although the hydrogen bond
63
64 between the sulfonamide moiety of the ligand and D569, as well as the hydrophobic interaction with L570,
65
66 was still preserved in the complex with the “chimeric” PYK2 structure, some interactions with β -strands

1
2
3
4 and the hinge loop (such as I428, V436, A452, V484, L501) lining the pocket entrance were less stable than
5
6 in FAK. This suggested that the protein-ligand interactions, particularly with β 1- β 4, were less optimal in
7
8 PYK2 relative to FAK even if the helical conformation of the DFG-motif was present in both structures.
9

10 We further explored the effect of the structural differences of the PYK2 and FAK binding sites by making
11
12 12 constructs with point mutations and subsequently performing NanoBRET target engagement assays
13
14 and wash-out experiments (**Fig. 6F-H, Fig. S5, Table S3**). First, we tested the interaction of the inhibitors
15
16 with FAK-L567 by mutating this residue to an alanine and hypothesized a change from slow to fast off-rate
17
18 as the missing hydrophobic interaction with the FAK protein. Indeed, the binding affinity of the inhibitor
19
20 series was lower for FAK L567A and, gratifyingly, the mutation changed the off-rates from slow to fast,
21
22 indicating a direct correlation of this residue and helix formation with dissociation kinetics (**Fig. 6G**). For
23
24 testing the role of the polar interaction of the oxindole and quinoline-2-ones with FAK R426, we mutated
25
26 it to alanine. In agreement with computational and crystallographic analysis, the potency did not change
27
28 for the FAK R426A mutant and we did not observe differences in the binding kinetics (**Fig. S5, Table S3**).
29

30 In the crystal structure, we observed a hydrogen bond between PYK2 E509 and the pyridine nitrogen of **1**
31
32 (**Fig. 1**) but this was not present for the equivalent FAK E506. In order to try to establish an interaction
33
34 between the ligand aromatic ring system and FAK, we mutated FAK E506 to glutamine, to test for an
35
36 electron donor, and to isoleucine to test for a hydrophobic interaction at this position. Both FAK E506Q
37
38 and FAK E506I showed decreased potency for the series of inhibitors, indicating this interaction to be
39
40 unfavourable in FAK (**Fig. S5, Table S3**). The P-loop of PYK2 is stabilized by a polar interaction of E432
41
42 sidechain (PYK2) with the backbone of G437. In FAK, the corresponding residue E430 pointed towards the
43
44 solvent and did not contribute to a stabilized P-loop. Using FAK-E430S and FAK-E430Q mutants, we
45
46 investigated whether we can establish the same P-loop rigidity as in PYK2, preventing the DFG helix from
47
48 forming. However, the mutant binding kinetics were similar to the wildtype FAK binding kinetics (**Fig. S5,**
49
50 **Table S3**). This result is also in accordance with the MD simulations showing that the hydrogen bond
51
52 between G566 and R432 was not strictly preserved. As we see a striking difference in the sequence of FAK
53
54 and PYK2 in PYK2-F435 (vs FAK Q432), we tested the PYK2 mutants F435Q and F435R. While the mutants
55
56 did not show a change in potency, we did observe a change to slower binding kinetics for PYK2 F435Q. As
57
58 E474 is located in helix α C in PYK2, rigidifies the protein, we mutated E474 to glutamine, which resulted in
59
60 a decreased potency but similar binding kinetics to WT PYK2 (**Fig. S5, Table S3**).
61

62 Lastly, we tested a potential involvement of protein phosphorylation in binding and kinetics by mutating
63
64 the respective Y576 and Y577 in FAK and Y579 and Y580 in PYK2 to phenylalanine. While in FAK we did not
65
66 observe a change in potency, the difference compared to PYK2 wild-type was a 2-fold increase in potency.

1
2
3
4 However, these mutations had no impact on binding kinetics. In summary, for PYK2, none of the mutants
5 showed a change from fast to slow dissociation for this series of inhibitors. As a representative for the
6 inhibitor set, we chose **10**, where only fast kinetics was observed for all PYK2 mutants (**Fig. 6H**). Based on
7 both the mutagenesis study and our MD simulations, we concluded that it is not one single amino acid
8 residue change that enables FAK to form a stable helical DFG-motif in complexes.
9
10

11 Significance

12
13
14
15
16
17
18 In this study, we explored the structural mechanism of amino-pyrimidine inhibitor binding, confirming
19 existing FAK SARs and providing a SKR study for FAK. We observed slow-binding inhibitors to induce a
20 helical DFG motif conformation in FAK and showed that the gained selectivity of inhibitor binding to FAK
21 and PYK2 was based on a change in their unbinding rates driven by several sequence dissimilarities in their
22 binding sites. This study demonstrates that small variations in the sequence of the protein binding site
23 may trigger different mechanisms of ligand-protein interactions and result in ligand-induced stabilization
24 of distinct protein conformations that affect ligand binding kinetics. We demonstrated that a combination
25 of structural data and *in silico* methods can be used to predict compound residence times and to obtain
26 insight into the molecular determinants affecting kinetics of inhibitors. We have shown here that the
27 NanoBRET wash-out technique provides a unique opportunity to explore target engagement and kinetic
28 behavior in living cells. The kinetic data translated into the *in cellulo* context of a NanoBRET wash-out assay
29 and validated the PF-431396 (**10**) SPR based residence time of 138 minutes in living cells. Nevertheless,
30 this cellular residence time of PF-431396 (**10**) was still short to significantly affect the pharmacology of **10**
31 indicating that future drug discovery efforts are necessary to optimize ligand kinetics in order to impact
32 clinical efficacy. Indeed, this amino-pyrimidine-series was developed into a macrocyclic inhibitor that
33 showed better selectivity for PYK2 (Farand et al., 2016). The hydrophobic interaction of inhibitors with the
34 helical activation loop in FAK should be included in future optimization processes for the development of
35 inhibitors showing prolonged residence time for FAK.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Acknowledgements

52
53
54 Funding: This work was supported by a Capes-Humboldt postdoctoral scholarship to A N-A (Capes process
55 number 88881.162167/2017-01), the European Union's Horizon 2020 Framework Programme for
56 Research and Innovation under the Specific Grant Agreement No. 785907 and No. 945539 (Human Brain
57
58
59
60
61
62
63
64
65

1
2
3
4 Project SGA2 and SGA3 to RCW), EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking, K4DD
5
6 (grant no. 115366) and the Klaus Tschira Foundation. BTB, MS, JME, SMK and SK are supported by the
7
8 Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510 and the SGC, a
9
10 registered charity (number 1097737) that receives funds from; AbbVie, Bayer AG, Boehringer
11
12 Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome
13
14 Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative
15
16 Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in
17
18 Canada and US), Merck & Co (aka MSD outside Canada and US), Pfizer, São Paulo Research Foundation-
19
20 FAPESP, Takeda and Wellcome. B-T., B and S.K. would like to acknowledge funding by the DFG funded CRC
21
22 SFB 1399.

23 Author Contributions

24
25
26 S.K., S.M., M.F., J.B., J.M.E., and R.W. supervised the research. T.H. synthesized the inhibitors. B-T.B, M.S.,
27
28 D.M., and M.A. performed structural studies. B-T. B, M.A., I.N., and J.W. performed biochemical and
29
30 biophysical binding studies. B-T. B and M.A. performed NanoBRET cell-based ligand studies. D.B.K, A.N-A.
31
32 and R.W. performed in silico analysis. S.K. M.A., D.B.K. and B-T. B drafted the manuscript, which has been
33
34 edited and approved by all authors.
35
36
37
38

39 Declaration of interests

40
41 M.F. J.B. and T.H. are employees of Merck KGaA, Darmstadt, Germany. M.A. was an employee of Merck
42
43 KGaA, Darmstadt, Germany at the time of experimental procedures and is now an employee of Sanofi-
44
45 Aventis Deutschland GmbH, Frankfurt, Germany. Other authors have no conflict of interest to declare.
46
47

48 Main figure titles and legends

49
50 **Fig. 1: Comparison of the binding modes of PF-562271 (1) in FAK (PDB 3bz3 (Roberts et al., 2008)) and**
51 **PYK2 (PDB 5tob (Farand et al., 2016)). A)** Chemical structure of PF-562271 (1) and complexes of FAK (cyan)
52 and PYK2 (grey) with PF-562271 (1, yellow). Kinase residues interacting with the inhibitor are highlighted
53 in blue (detailed analysis in **Table S1**), hydrogen bonds are indicated by dashes. The DFG motif is depicted
54 in orange for both kinases. Analysis of the interface between FAK and PF562271 (**B**, blue) and PYK2 and
55 PF562271 (**C**, gray). Shown is the Buried Surface Area (BSA) normalized by the Accessible Surface Area
56 (ASA) per residue. Compound structure was drawn using Biovia Draw 2017, models were depicted using
57 PyMol 1.7.6.2 and bar charts were created using GraphPad Prism 8.
58
59
60
61
62
63
64
65

1
2
3
4 **Fig. 2: L567-ligand interactions increased potency and prolonged residence times in FAK.** Slow off-rate
5 inhibitors induce a helical conformation of the activation loop in FAK. **A-F:** The top of each panel shows
6 the chemical structure of compounds (**2, 3, 4, 5, 8, 10**) and their respective residence times τ of the
7 inhibitor-FAK complexes. Shown below are the determined inhibitor bound FAK structures (FAK (cyan),
8 inhibitors (yellow)) with highlighted DFG segment in orange. Dashes indicate hydrogen bonds. On the
9 bottom of each panel amino acid residues contributing to the interface between FAK and the inhibitor are
10 shown. Displayed is the Buried Surface Area (BSA) normalized by the Accessible Surface Area (ASA)
11 per residue (detailed analysis in **Table S1**). PDB codes: 6yt6 (**2**), 6yxv (**3**), 6yq1 (**4**), 6yoj (**5**), 6yvs (**8**), 6yr9 (**10**).
12 Compound structure was drawn using Biovia Draw 2017, models were depicted using PyMol 1.7.6.2 and
13 bar charts were created using GraphPad Prism 8.

14
15
16
17 **Fig. 3: The selectivity profile of FAK and PYK2 is dictated by the formation of a helical conformation of**
18 **the DFG motif in FAK. A)** Overlay of crystal structures of the complexes of FAK-**10** (blue and yellow, PDB
19 code: 6yr9) and PYK2-**10** (gray and magenta, PDB code: 3fzr (Han et al., 2009)), **B)** Overlay of the complexes
20 of FAK-**12** (blue and yellow, PDB code: 6yvy) and PYK2-**12** (gray and magenta, PDB code: 3h3c (Walker et
21 al., 2009)). Models were depicted using PyMol 1.7.6.2.

22
23
24 **Fig. 4: Protein flexibility and the dynamics of the protein-ligand interactions differ for FAK and PYK2.** The
25 analysis of MD simulations of complexes of ligands with PYK2 and FAK is shown along with computed
26 relative residence times: **A)** RMSF of the ligand and three regions of the binding site (β 1, α C and the DFG
27 loop corresponding, respectively, to FAK residues 421-434, 451-471, and 563-570) averaged over four MD
28 trajectories (80ns in total) and shown for 12 compounds for FAK and PYK2. **B, C)** Protein-ligand interaction
29 fingerprint maps for ligand-protein complexes obtained from the last 300 frames of four 20ns conventional
30 MD simulations for FAK **B)** and PYK2 **C)**. The occurrence of hydrogen-bonds (HD/HA), aromatic (AR),
31 hydrophobic (HY), and water-mediated (WB) protein-ligand interactions is shown by the colour (white –
32 not observed, dark blue – present in all snapshots analysed). The SPR residence times are shown on a
33 logarithmic scale for all compounds in the right-hand plots. **D)** View of compound **1** and residues in FAK
34 that contribute to the protein-ligand interactions shown in **B)**. **E)** Correlation between computed relative
35 residence times (τ_{RAMD}) and $1/k_{off}$ values measured by SPR for FAK and PYK2; $R^2=0.91$ for the entire set of
36 the data ($R^2=0.95$ and 0.63 for the FAK and PYK2 subsets, respectively). Compound **3** simulated starting
37 from a complex with a helical conformation of the DFG-motif in PYK2 is denoted by “(3)” (see text and **Fig.**
38 **S4A**). Figures were created using Python (library Matplotlib) and models were depicted using PyMol
39 1.7.6.2.

40
41
42
43 **Fig. 5: Binding potency and kinetics of FAK and PYK2 in living cells. A)** Target engagement assays for FAK
44 and PYK2 for **1** and **10** as indicated in the figure legend. **B)** Correlation of the in cellulo potency with the
45 potency determined in vitro by SPR. **C)** NanoBRET wash-out experiments for **1** and **10** in comparison to
46 background data and tracer only (DMSO added instead of test compound). Figures were created using
47 GraphPad Prism 8.

48
49
50
51 **Fig. 6: Structural stability of the ligand binding sites in FAK and PYK2 explored by computations and by**
52 **experimental site-directed mutagenesis: (A-E) Computations: (A,B)** Binding site in FAK (left, PDB ID 3bz3)
53 and PYK2 (right, PDB ID 3et7) indicating residues that may affect protein flexibility (see discussion in the
54 main text) in stick representation; **(C, E)** Results of simulations of unbound FAK and “chimeric” PYK2
55 structures with a helical conformation of the DFG-motif: **(C)** Variation of the structures of FAK (grey) and
56 chimeric PYK2 (beige) in conventional MD simulations (four frames are shown for each protein); L570 in
57 PYK2 is highlighted in orange, the ligand position in a FAK complex is shown for compound **1** (PDB ID 3bz3);
58 **(E)** Fraction of MD frames where hydrogen bonds between six residues of the DFG-motif helix and the rest
59 of the protein were observed; **(D)**: Protein-ligand interaction fingerprint map for compound **3** bound to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FAK and PYK2 (with helical or loop conformation of the DFG motif (see Fig.4B for key); residues are labelled by the name and number in the FAK structure; **(F-H): Site directed mutagenesis: (F)** NanoBRET potency for mutant constructs displayed as a ratio of pIC_{50} Mutant / Wild-Type for mutants as indicated in the figure. **(G-H)** Representative wash-out experiment for **10** on the mutants tested for FAK **(G)** and PYK2 **(H)**. The signal was normalised to the tracer control and fitted using a one phase exponential decay. Models A-C were created using PyMol 1.7.6.2, Figures D-E and figures F-H were created using Python (library Matplotlib) and GraphPad Prism 8, respectively.

Main tables and legends












Cmpd No (Name)				FAK (SPR)			PYK2 (SPR)		
	R ¹	R ²	R ³	k_{on} [10 ⁵ /Ms]	k_{off} [10 ⁻² /s]	K_D [nM]	k_{on} [10 ⁵ /Ms]	k_{off} [10 ⁻² /s]	K_D [nM]
1 PF-562271			-CF ₃	53±20.0	0.34±0.078	0.76±0.35	130±43	7.4±2.5	5.7±1.0
2			-H	8.8±2.4	29±8.8	320±27	9.0±3.3	75±32	820±96
3			-CF ₃	0.87±0.22	0.62±0.24	70±22	0.37±0.15	1.7±0.7 8	470±100
4			-CF ₃	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
5 PF-573228			-CF ₃	70.2±36	0.82±0.22	1.3±0.32	13±4.8	33±11	250±19
6			-CF ₃	17±10	6.1±4.2	37±7.0	17±6.6	19±7.8	110±4.0
7			-CF ₃	1.4±0.44	14±3.0	1000±23	No binding		
8			-CF ₃	48±20	7.1±3.0	15±2.6	13±8.4	25±11	230±92
9			-CF ₃	1.8±0.51	4.8±1.3	260±21	No binding		
10 PF-431396			-CF ₃	30.8±14	0.054±0.027	0.18±0.05	58±15	4.0±1.2	6.9±0.54
11 PF-8554878 defactinib			-CF ₃	24±5.8	0.44±0.061	1.9±0.50	15±3.8	3.6±1.1	24±3.1
12 PF-719			-CF ₃	14±6.5	20±8.3	150±19	22±8.1	5.5±2.4	25±3.3

Table 1: Design of a series of inhibitors probing the structure activity relationship in FAK and PYK2. Three substituent sites on the pyrimidine core structure of **1**, R¹ (solvent exposed), R² (DFG adjacent) and R³ (back pocket) were considered to study the interactions in the kinase binding sites. SPR= Surface Plasmon Resonance, k_{on} = association rate constant, k_{off} = dissociation rate constant, K_D = equilibrium dissociation constant, n.d.= not determined.

STAR*Methods

- RESOURCE AVAILABILITY
 - Lead Contact
 - Materials Availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Microbe strains
 - Cell lines
- METHOD DETAILS
 - Compound Chemistry
 - Protein Expression and Purification
 - Crystallization and Structure Determination
 - Surface Plasmon Resonance
 - NanoBRET cellular assays
 - NanoBRET plasmid mutation
 - Computations
 - Computational preparation of structures
 - Docking of compounds to PYK2
 - Modeling of PYK with a FAK-like DFG helix
 - MD and τ RAMD simulations
 - Analysis of MD trajectories
- QUANTIFICATION AND STATISTICAL ANALYSIS
 - Surface-Plasmon-Resonance-Data
 - NanoBRET Data

RESOURCE AVAILABILITY

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stefan Knapp (knapp@pharmchem.uni-frankfurt.de).

Material Availability

Requests for plasmids generated in this study should be directed to the lead contact. Inhibitors used in this study can be obtained from commercial sources or for inhibitors generated in this study requests can be directed to Timo Heinrich.

Data and code availability

The coordinates and structure factors of all complexes have been deposited to the protein data bank under accession codes: 6YT6, 6YXV, 6YQ1, 6YOJ, 6YVS, 6YR9, 6YVY.

Experimental Model and Subject Details

Microbe strains

Escherichia coli, BL21 (DE3) strain was used for recombinant protein expression. Cells were cultured in terrific broth media at 37°C until they reached an OD600 of 2.6-3.0 prior to induction with 0.5 mM IPTG for protein expression at 18°C overnight.

Cell lines

HEK293T (female) cells were obtained from ATCC (identifier CRL-3216). Cells were cultured at 37°C/5% CO₂ in DMEM (Gibco) supplemented with 10% heat inactivated FBS (Invitrogen) and penicillin-streptavidin antibiotic (Gibco).

Method Details

Compound Chemistry.

General synthesis of diaminopyrimidines **1 -6, 8, 10 - 12**

The synthetic steps were performed as described in the patent literature (Arcari et al., 2006; Kath and Luzzio, 2003; Luzzio et al., 2008; Matsuhisa et al., 2001) and are described in detail below.

*Synthesis of N-Methyl-N-(3-{{2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino}-methyl}-pyridin-2-yl)-methanesulfonamide (PF- 562271) (**1**)*

The reaction of 5-trifluoromethyl-2,4-dichloropyrimidine and 5-amino-oxindole in a tert butanol/dichloroethane = 1:1 and zinc chloride yielded the intermediate 5-{{4-chloro-5-(trifluoromethyl)pyrimidin-2-yl}amino}-2,3-dihydro-1H-indol-2-one with 59%. This compound reacted with N-[3-(aminomethyl)pyridin-2-yl]-N-methylmethanesulfonamide dihydrochloride in DMF and 2.5 eq of sodium carbonate at 85°C over night to the final product in 36% yield. The yield for the final step was optimized by reaction in toluene/isopropanol = 1:1 in the presence of 1.2 eq of diisopropylethylamine to 72%.

¹H NMR (500 MHz, DMSO-*d*₆) δ 10.16 (s, 2H), 9.37 (s, 1H), 8.44 (dd, *J* = 4.7, 1.8 Hz, 3H), 8.21 (s, 3H), 7.67 (d, *J* = 8.0 Hz, 3H), 7.50 – 7.44 (m, 3H), 7.42 (dd, *J* = 7.8, 4.7 Hz, 3H), 7.33 (s, 2H), 7.19 (d, *J* = 8.3 Hz, 2H), 6.54 (d, *J* = 8.3 Hz, 2H), 4.77 (d, *J* = 5.8 Hz, 5H), 4.03 (q, *J* = 7.1 Hz, 2H), 3.15 (s, 9H), 3.11 (s, 7H), 1.99 (s, 3H), 1.18 (t, *J* = 7.1 Hz, 3H).

*Synthesis of N-Methyl-N-(3-{{2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino}-methyl}-pyridin-2-yl)-methanesulfonamide (**2**)*

1
2
3
4 The intermediate N-(3-[(2-chloropyrimidin-4-yl)amino]methyl)pyridin-2-yl)-N-
5 methylmethanesulfonamide was obtained in 27% yield by reaction of 2,4-dichloropyrimidine and N-[3-
6 (aminomethyl)pyridin-2-yl]-N-methylmethanesulfonamide in the microwave at 120°C for 20 minutes in
7
8 the presence of 2 eq of triethyl amine. The final product was obtained after reaction of the intermediate
9
10 with 5-aminoindole under identical conditions in 30% yield as brown solid.

11
12
13 ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.11 (s, 2H), 8.76 (s, 2H), 8.45 (dd, *J* = 4.7, 1.9 Hz, 2H), 8.15 (s, 3H), 7.85
14 – 7.79 (m, 4H), 7.56 (s, 2H), 7.52 (s, 2H), 7.44 (dd, *J* = 7.7, 4.7 Hz, 2H), 7.39 – 7.33 (m, 2H), 6.59 (d, *J* = 8.4
15 Hz, 2H), 5.99 – 5.95 (m, 1H), 4.65 (d, *J* = 5.9 Hz, 3H), 3.17 (d, *J* = 7.1 Hz, 13H).

16
17
18
19 *Synthesis of N-Methyl-N-{3-[(2-phenylamino-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl]-pyridin-2-yl}-*
20 *methanesulfonamide (3)*

21
22
23 The intermediate 4-chloro-N-phenyl-5-(trifluoromethyl)pyrimidin-2-amine was obtained in 58 % yield by
24 reaction of 5-trifluoromethyl-2,4-dichloropyrimidine and aniline in dichloromethane/tert-butanol = 1:1 in
25 the presence of stoichiometric amounts of zing chloride-diethylether complex and triethyl amine at RT over
26
27 night. The final product could be isolated in 40% yield by reaction of the intermediate with N-[3-
28 (aminomethyl)pyridin-2-yl]-N-methylmethanesulfonamide in toluene/isopropanol = 1:1 at 80°C over night
29
30 and column chromatography.

31
32
33 ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.54 (s, 1H), 8.44 (dd, *J* = 4.7, 1.9 Hz, 1H), 8.26 (s, 1H), 7.66 (dd, *J* = 7.7,
34 1.9 Hz, 1H), 7.58 (t, *J* = 5.9 Hz, 1H), 7.42 (dt, *J* = 7.9, 4.5 Hz, 3H), 7.08 (t, *J* = 7.7 Hz, 2H), 6.88 (t, *J* = 7.3 Hz,
35 1H), 4.81 (d, *J* = 5.7 Hz, 2H), 3.15 (d, *J* = 11.9 Hz, 6H).

36
37
38
39
40 *Synthesis of N-Methyl-N-(3-{[2-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-ylamino)-5-trifluoromethyl-pyrimidin-*
41 *4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide (4)*

42
43
44 Reaction of 5-drifluoromethyl-2,4-dichloropyrimidine and 6-amino-3,4-dihydroquinolin-2(1H)-one in tert
45 butanol/dichloromethane in the presence of zinc chloride gave the intermediate 6-(4-Chloro-5-
46 (trifluoromethyl)pyrimidine-2-ylamino-3,4-dihydroquinoline-2(1H)-one in 64% yield. This compound
47
48 reacted to the final product in 31% yield with N-[3-(aminomethyl)pyridin-2-yl]-N-
49
50 methylmethanesulfonamide.

51
52
53 ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.89 (s, 1H), 9.45 – 9.33 (m, 1H), 8.43 (dd, *J* = 4.8, 1.8 Hz, 1H), 8.23 – 8.21
54 (m, 1H), 7.68 (d, *J* = 7.7 Hz, 1H), 7.49 (t, *J* = 5.8 Hz, 1H), 7.41 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.32 – 7.26 (m, 1H),
55 7.19 (d, *J* = 8.5 Hz, 1H), 6.60 (d, *J* = 8.6 Hz, 1H), 4.79 (d, *J* = 5.7 Hz, 2H), 3.14 (s, 3H), 3.14 – 3.11 (m, 3H),
56 2.66 – 2.57 (m, 2H), 2.36 – 2.31 (m, 2H).

1
2
3
4 *Synthesis of 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-*
5 *1H-quinolin-2-one (PF-573228) (5)*
6

7
8 The intermediate from the preparation of compound **4** reacted with (3-(methylsulfonyl)phenyl)
9 methanamine HCl salt in NMP in the presence of 3 eq of triethylamine to the final compound in 70% yield.
10

11
12 ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.89 (s, 1H), 9.44 (br. s, 1H), 8.16 (s, 1H), 7.83 – 7.76 (m, 3H), 7.56 – 7.54
13 (m, 2H), 7.34 (s, 1H), 7.19 (d, *J* = 7.3 Hz, 1H), 6.64 (d, *J* = 8.7 Hz, 1H), 4.70 (d, *J* = 5.5 Hz, 2H), 3.34 (s, 3H),
14 2.63 (t, *J* = 7.3 Hz, 2H), 2.34 (t, *J* = 11 Hz, 2H).
15

16
17 *Synthesis of 5-({4-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)-2,3-*
18 *dihydro-1H-indol-2-one (6)*
19

20
21 The intermediate 5-{{4-chloro-5-(trifluoromethyl)pyrimidin-2-yl}amino}-2,3-dihydro-1H-indol-2-one
22 obtained for the synthesis of **8** was repeated with an access of 5-amino-oxindole and the final product was
23 isolated in 77% after chromatography.
24

25
26
27 ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.44 (s, 2H), 10.16 (s, 2H), 9.47 (s, 1H), 8.56 (s, 1H), 8.26 (s, 2H), 7.43 (s,
28 2H), 7.24 – 7.16 (m, 6H), 6.84 (d, *J* = 8.1 Hz, 2H), 6.55 (d, *J* = 8.4 Hz, 2H), 3.47 (s, 4H).
29

30
31
32 *Synthesis of 5-{4-[(Pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-*
33 *one (8)*
34

35
36 To solution of 5-trifluoromethyl-2,4-dichloropyrimidine in 1:1 DCE/tBuOH was added Zinc chloride 1 M
37 solution in ether. After 0.5 hour, 5-amino-oxindole was added followed by triethylamine keeping
38 temperature at 25°C. The reaction was allowed to stir at room temperature overnight, then was
39 concentrated and the product triturated (repeated several times, slightly soluble in MeOH) from methanol
40 as a yellow solid (5-{{4-chloro-5-(trifluoromethyl)pyrimidin-2-yl}amino}-2,3-dihydro-1H-indol-2-one, 65%
41 yield). This intermediate was dissolved in DMF and 1-(pyridin-3-yl)methanamine and sodium carbonate
42 were added. The mixture reacted for 3 days at RT and the final product could be obtained after
43 chromatography in 34% yield.
44

45
46
47 ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.21 (s, 1H), 9.41 (s, 1H), 8.53 (s, 1H), 8.42 (dd, *J* = 4.9, 1.7 Hz, 1H), 8.17
48 (d, *J* = 5.3 Hz, 2H), 7.73 (t, *J* = 6.0 Hz, 1H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.38 (s, 1H), 7.33 (dd, *J* = 7.8, 4.7 Hz,
49 1H), 7.24 (d, *J* = 8.3 Hz, 1H), 6.65 (d, *J* = 8.4 Hz, 1H), 4.64 (d, *J* = 5.9 Hz, 2H).
50

51
52
53
54
55 *Synthesis of N-Methyl-N-(2-{{2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-*
56 *ylamino}-methyl}-phenyl)-methanesulfonamide (PF-431396) (10)*
57
58

1
2
3
4 The intermediate 5-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}-2,3-dihydro-1H-indol-2-one
5 prepared for the synthesis of compound **8** was reacted with N-[2-(aminomethyl)phenyl]-N-
6 methylmethanesulfonamide under identical conditions and yielded the title compound in 45% yield.
7
8

9
10 ¹H NMR (400 MHz, DMSO) δ 10.24 (s, 1H), 9.75 (br. s, 1H), 8.26 (s, 1H), 7.76 (br. s, 1H), 7.56 – 7.53 (m,
11 1H), 7.41 – 7.32 (m, 3H), 7.27 – 7.22 (m, 2H), 6.62 – 6.60 (m, 1H), 4.81 – 4.79 (m, 2H), 3.32 – 3.27 (m, 2H),
12 3.12 – 3.09 (m, 6H).
13

14
15 *Synthesis of 4-(4-[[3-(Methanesulfonyl-methyl-amino)-pyrazin-2-ylmethyl]-amino]-5-trifluoromethyl-
16 pyrimidin-2-ylamino)-N-methyl-benzamide (PF-04554878) (**11**)*
17

18
19 The reaction of N-(3-Aminomethyl-pyrazin-2-yl)-N-methyl-methanesulfonamide and 2,4-Dichloro-5-
20 trifluoromethyl-pyrimidine in dichloromethane in the presence of diisopropylethylamine from -20°C to 0°C
21 yielded the intermediate N-{3-[(2-Chloro-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl]-pyrazin-2-yl}-N-
22 methyl-methanesulfonamide in 32% yield. The final product was obtained by reaction of this intermediate
23 with 4-amino-N-methyl-benzamide in butanol and catalytic amounts of acetic acid from RT to 100°C in
24 14% yield.
25
26
27
28
29

30 ¹H NMR (400 MHz, DMSO) δ 9.84 (s, 1H), 8.68-8.67 (d, J = 4 Hz, 1H), 8.57-8.56 (d, J = 4Hz, 1H), 8.30 (s,
31 1H), 8.20-8.19 (s, J = 4 Hz, 1H), 7.65-7.58 (m, 3H), 7.43 (s, 1H), 4.99-4.98 (d, 2H), 3.21-3.18 (d, 6H), 2.74-
32 2.73 (d, 3H)
33
34
35
36
37

38 General procedure for the preparation of aminopyrimidines **7** and **9**.

39
40 Intermediate 5-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}-2,3-dihydro-1H-indol-2-one from the
41 synthesis of compound **8** was coupled to the corresponding aryl acetylene in the presence of catalytic
42 amounts of bistriphenylphosphine palladiumdichloride, copper(I)iodide and two equivalents of
43 triethylamine in DMF at 100°C under N₂ atmosphere to the corresponding diaryl-acetylene. The triple bond
44 was reduced on Pd/C contact at room temperature under an atmosphere of H₂ for 1h in methanol.
45
46
47
48
49

50 *Synthesis of 5-{4-[2-(4-Fluoro-phenyl)-ethyl]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-
51 one (**7**)*
52

53
54 The intermediate 5-({4-[2-(4-fluorophenyl)ethynyl]-5-(trifluoromethyl)pyrimidin-2-yl}amino)-2,3-dihydro-
55 1H-indol-2-one was obtained in 92% and the final product in 75% yield.
56
57

58 ¹H NMR (400 MHz, DMSO) δ 10.31 (s, 1H), 10.07 (s, 1H), 8.61 (s, 1H), 7.58 (s, 1H), 7.48 (d, J = 8.6 Hz, 1H),
59 7.24 7.24 (dd, J = 8.2 Hz, 5.8 Hz, 2H), 7.10 (t, J = 8.8 Hz, 2H), 6.76 (d, J = 8.4 Hz, 1H), 3.48 (s, 2H), 3.13 –
60 2.93 (m, 4H).
61
62
63
64
65

1
2
3
4
5
6
7 *Synthesis of 5-(4-Phenethyl-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one (9).*

8
9 The intermediate 5-{{4-(2-phenylethynyl)-5-(trifluoromethyl)pyrimidin-2-yl}amino}-2,3-dihydro-1H-indol-
10 2-one was obtained in 90% and the final product in 80% yield.

11
12
13 ¹H NMR (400 MHz, DMSO) δ 10.31 (s, 1H), 10.07 (s, 1H), 8.61 (s, 1H), 7.58 (s, 1H), 7.48 (d, *J* = 8.6 Hz, 1H),
14 7.29 (t, *J* = 7.4 Hz, 2H), 7.20 (dd, *J* = 15.2 Hz, 7.1 Hz, 3H), 6.76 (d, *J* = 8.4 Hz, 1H), 3.48 (s, 2H), 3.03 (s, 4H).

15
16 *Protein Expression and Purification.*

17
18 Human FAK kinase domain was expressed and purified by Instituto de Biología Experimental e Tecnológica.
19 The FAK catalytic domain used for crystallization experiments and SPR assays was expressed with an NH₂-
20 terminal 6XHis-tag and comprises residues 410 to 689 after thrombin cleavage (FAK sequence with residue
21 410 changed from a Pro to a Gly). FAK was expressed in Hi5 insect cells using the Bac Magic kit (Invitrogen
22 Corp.) Cells were harvested by centrifugation and resuspended in lysis buffer (20 mM Na-P, 500 mM NaCl,
23 0.1% NP 40, 5 mM MgCl₂, pH 7.5, 1 mM DTT, benzonase and protease inhibitor cocktail III). Cells were
24 lysed by high pressure homogenization and cleared by centrifugation at 31.000x g for 40 min at 4 °C. The
25 supernatant was loaded onto a Ni-NTA affinity column and the target protein was eluted in step gradient
26 with buffer 20 mM Na-P, 500 mM NaCl, 500 mM Imidazole, 1 mM DTT, pH 7.5. Peak fractions *were desalted*
27 and treated with hu-alpha Thrombin for histidine tag removal. The cleaved proteins were separated by
28 passing through Ni-Sepharose resin and further purified using size-exclusion chromatography (Superdex
29 75 26/60). The resultant pure recombinant FAK was concentrated to 5.9 mg/mL and stored at -80 °C in a
30 buffer containing 10 mM HEPES, 200 mM ammonium sulfate, and 0.1 mM TCEP, pH 7.5.

31
32
33 The human PYK2 kinase domain used for SPR measurements was expressed with an NH₂-terminal 6XHis-
34 tag and comprised residues 420-691. PYK2 was cloned into pET28a including an N-terminal HIS-TEV-tag
35 and expressed in Escherichia coli Rosetta 2 (DE3) cells. Cells were harvested by centrifugation and
36 resuspended in lysis buffer (20 mM Na-P, 500 mM NaCl, 1 mM DTT, 20 mM Imidazole, 5 mM MgCl₂, pH
37 7.5, protease inhibitor cocktail III and Benzonase). Cells were lysed by high pressure homogenization and
38 cleared by centrifugation at 20.400x g for 60 min at 4 °C. Subsequent steps were similar to previously
39 described for FAK. The resultant pure recombinant PYK2 was concentrated to 10.7 mg/mL and stored at
40 -80 °C in a buffer containing 30 mM HEPES, pH 7.5, 150 mM NaCl, 0.1 mM EGTA, 1 mM DTT.

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 *Crystallization and Structure Determination.*

57
58 FAK was incubated for 2 hours with 2 mM adenosine 5'-triphosphate magnesium salt. Crystals were
59 obtained using the hanging drop vapor diffusion method and equilibrating against 1 mL of the reservoir
60
61
62
63
64
65

1
2
3
4 solution (0.2 M Magnesium formate dihydrate, 10-20% PEG 3350) at 20°C. The protein was mixed 1:1 with
5
6 the reservoir solution. For complex formation with the inhibitor, the crystals were transferred to a
7
8 stabilizing solution (0.2 M Magnesium formate dihydrate, 30% PEG 3350) containing 5 mM 1 and 5% DMSO
9
10 and were soaked for 24 h. All data sets were collected at 100 K on beamline SLS X106 and processed with
11
12 the XDS software package (Kabsch, 2010). The structures were solved by molecular replacement, using
13
14 BUSTER (Bricogne et al., 2016). Model building was performed in Coot (Emsley, 2017), with compounds
15
16 and waters fitted into the initial $|F_o| - |F_c|$ map, and the structures were refined using BUSTER. The
17
18 coordinates of the holo-structures of FAK have been deposited in the RCSB Protein Data Bank. The
19
20 refinement statistics and PDB accession codes are given in **Table S2**.

21
22 Protein -ligand interfaces were calculated using the PISA webserver (Krissinel and Henrick, 2007). Buried
23
24 Surface Area (BSA, in Å²) and Accessible Surface Area (ASA, in Å²) were calculated per residue and
25
26 normalized by dividing the BSA by ASA. Figures contain the interface profile of one chain of the asymmetric
27
28 unit.

29 *Surface Plasmon Resonance.*

30
31 SPR measurements were performed on a Biacore 4000 instrument from GE Healthcare. Recombinant FAK
32
33 [huFAK (410-689)] and PYK2 [huFAK (420-691)] were immobilized on a Biacore CM5 chip at 25°C at a flow
34
35 rate of 10 µL/min using amine coupling at pH 4.50 and pH 5.0 respectively, according to Biacore's standard
36
37 protocol. HBS-N (10 mM Hepes pH 7.40, 0.15 M NaCl, 0,05 % Tween-20) served as running buffer during
38
39 immobilization. FAK and PYK2 were applied at a concentration of 5 µg/mL in a buffer containing a 60-fold
40
41 excess of PF-431396. An unmodified carboxydextran matrix served as a reference surface. FAK and PYK2
42
43 inhibitors stored as 10 mM stock solutions in 100% dimethyl sulfoxide (DMSO) were dissolved in running
44
45 buffer (20 mM HEPES pH 7.50, 150 mM NaCl, 0.05% Tween 20, 1 mM DTT, 0.1 mM EDTA, 2% DMSO) and
46
47 analyzed using two-fold dilution series. Kinetic titration experiments were performed at 25°C with a flow
48
49 rate of 30 µL/min, a sample contact time of 120 s and a dissociation time between 300 and 600 s. Data
50
51 sets were processed and analyzed using the Biacore 4000 Evaluation software, version 1.1. Solvent
52
53 corrected and double-referenced association and dissociation phase data were fitted to a simple 1:1
54
55 interaction model with mass transport limitations.

56 *NanoBRET cellular assays.*

57
58 The NanoBRET cellular target engagement assay is a tracer displacement assay. A BRET can here be
59
60 observed between the NLuc (tagged to the full-length protein kinase) and the tracer molecule used (a
61
62 commercial tracer that uses a BODIPY fluorophore) in living cells that were transiently transfected 20 h
63
64
65

1
2
3
4 prior to assay performance. A compound of interest that binds to the protein kinase displaces the tracer
5 and thereby reduces the BRET signal in a dose-dependent manner. The FAK and PYK2 NanoBRET assays
6 that were performed here were conducted as described before (Röhm et al., 2019; Vasta et al., 2018). In
7 brief: full-length FAK and PYK2 ORF (Promega) cloned in frame with a N-terminal NanoLuc-fusion and C-
8 terminal NanoLuc-fusion, respectively, were transfected into HEK293T cells and proteins were allowed to
9 express for 20h. For the target engagement assay serially diluted inhibitor and NanoBRET Kinase Tracer K5
10 (Promega) at 1 μ M for FAK and at 2 μ M for PYK2, respectively, were pipetted into white 384-well plates
11 (Greiner 781 207). The corresponding FAK or PYK2-transfected cells were added and reseeded at a density
12 of 2×10^5 cells/mL after trypsinization and resuspending in Opti-MEM without phenol red (Life
13 Technologies). The system was allowed to equilibrate for 2 hours at 37°C/5% CO₂ prior to BRET
14 measurements. To measure BRET, NanoBRET NanoGlo Substrate + Extracellular NanoLuc Inhibitor
15 (Promega) was added as per the manufacturer's protocol, and filtered luminescence was measured on a
16 PHERAstar plate reader (BMG Labtech) equipped with 450 nm BP filter (donor) and 610 nm LP filter
17 (acceptor). Competitive displacement data were then graphed using GraphPad Prism software using a 4-
18 parameter curve fit with the following equation: $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogIC}_{50} - X) * \text{HillSlope}))}$
19
20
21
22
23
24
25
26
27
28
29
30
31

32
33 For the kinetic wash-out assay, the inhibitor at a concentration of 10 times its previously determined IC_{50}
34 was pipetted into white 384-well plates (Greiner 781 207) and the corresponding FAK or PYK2-transfected
35 cells were added and reseeded at a density of 2×10^5 cells/mL after trypsinization and resuspending in
36 Opti-MEM without phenol red (Life Technologies). The system was allowed to equilibrate for 2 hours at
37 37°C/5% CO₂ to reach approximately 90% target occupancy prior to the wash-out via removal of the
38 medium to extract any unbound inhibitor and addition of the removed volume of Opti-MEM medium. The
39 tracer was added prior to BRET measurements at a final concentration as described for the target
40 engagement assays. To measure BRET, NanoBRET NanoGlo Substrate + Extracellular NanoLuc Inhibitor
41 (Promega) was added as per the manufacturer's protocol, and filtered luminescence was measured on a
42 PHERAstar plate reader (BMG Labtech) equipped with 450 nm BP filter (donor) and 610 nm LP filter
43 (acceptor) for 2h. The preincubated and saturated inhibitor-target complex dissociates during the wash-
44 out and the tracer added associates which results in an increasing BRET signal. The Background of the
45 kinetic data were corrected and then graphed using GraphPad Prism software using a one-phase
46 association fit with the following equation: $Y = Y_0 + (\text{Plateau} - Y_0) * (1 - \exp(-K * x))$
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

NanoBRET plasmid mutation.

Plasmids obtained by PROMEGA were point-mutated using Quickchange Mutagenesis with Hercul polymerase (Agilent). PCR cycles were prolonged to 35 cycles to obtain sufficient amounts of plasmid. PCR products were then transformed into *E.coli* MACH1 and potential clones sequenced for positive DNA sequence. DNA obtained was then amplified and purified using Midi-Prep Kits (QIAGEN) and used in the NanoBRET experiments as described above.

Computations

Computational preparation of structures

For FAK, we employed crystal structures for 8 complexes (compounds **1**, **2**, **3**, **4**, **5**, **8**, **10** and **12**, PDB IDs 3bz3, 6yt6, 6yxv, 6yq1, 6yoj, 6yvs, 6yr9 and 6vyv, respectively). The structure of the complex with compound **11** was built by similarity with **1** (PDB 3bz3). The FAK-bound structures of compounds **7** and **9** were modelled using the complex with **8** as a template (PDB 6yvs). For compound **9**, we employed both DFG loop-type and helix-type conformations of FAK to build complexes and performed simulations with both structures (see **Fig. S4**).

For PYK2, we employed crystal structures for 3 complexes (compounds **1**, **10** and **12**, PDB IDs 5TOB (Farand et al., 2016), 3FZR (Han et al., 2009) and 3H3C (Walker et al., 2008), respectively). In the structures from PDB files 3FZR and 3H3C, there was a missing region (residues 573-584 and 571-584, respectively). This region was modeled using the Sphinx web server to model loops (Marks et al., 2017). The structure of PDB file 3FZR was used as input. The missing region in PDB file 3H3C was modeled using PDB file 3FZR as a reference. In the structure from PDB file 5TOB, there were four regions missing (residues 446, 461-465, 495-496 and 570-587). Residues 570-587 were modeled using the RCD+ web server to model loops (López-Blanco et al., 2016). The remaining regions were modeled using the PDB file 3FZR as a reference. Missing side chains were added using the WHATIF web server (Vriend, 1990). The protonation state of the histidine residues and charged residues at pH 7.4 was checked using pdb2pqr (Dolinsky et al., 2007; Dolinsky et al., 2004). To keep consistency among the different structures, their residues were modeled with the same protonation states. Residues were assigned unusual protonation states only when such a state appeared in two or more structures. GLU 617 was protonated because it had a pKa value higher than 7.4 in two different structures.

Docking of compounds to PYK2

Complexes for compounds without a crystal structure available were modeled using the protein coordinates and the ligand pose in the PDB file 3FZR as a reference. Compounds **4** and **5** had bulkier substitutions compared to **10** in 3FZR, so their positions were modeled by docking. Compound **2** had a

1
2
3
4 substitution to a less bulky group, and its position was also modeled by docking. Docking of compounds **2**,
5 **4**, and **5** to PYK2 (PDB 3FZR) was done with AutoDock Vina (Trott and Olson, 2010). Grids with 0.375 Å
6 spacing and 70 points along each side were centered in the known binding site. Rotation about bond
7 torsions was allowed in ligands and the protein structure was kept frozen. The most favorable binding
8 pose making two hydrogen bonds with Tyr 505 (known to be important interactions from crystal
9 structures) was used for simulations.

15 Modeling of PYK2 with a FAK-like DFG-motif helix

16
17 A model of PYK2 with an FAK-like DFG-motif helix was built to understand why PYK2 is not able to form
18 this structure. The structures of PYK2 (PDB 3FZR) and FAK (PDB 3BZ3) were aligned using PyMol and the
19 coordinates of the atoms of the DFG-motif helix of FAK and residues nearby (residues 562-569) were used
20 to replace the original coordinates in PYK2 (residues 565-572). Moreover, a mutation to Cys at position
21 462 was introduced in PYK2 to create the same disulfide bond present in FAK (residues 456 and 459 in FAK,
22 residues 459 and 462 in PYK2). New rotamers for Glu 474 and Lys 457 in PYK2 were selected using PyMol
23 to avoid steric clashes with the inserted DFG-motif helix. Missing residues 573-584 were modeled using
24 the Sphinx web server to model loops (Marks et al., 2017). The structure of PYK2 containing the DFG-motif
25 helix was used as input. Missing side chains were added using the WHATIF web server (Vriend, 1990).
26 Crystallographic waters from PDB 3FZR were kept in the structure of PYK2 with the DFG-motif helix. The
27 protonation states of the residues were kept the same as those defined for WT PYK2 (PDB 3FZR). To
28 evaluate the effect on protein stability of the disulphide bridge that is located in the loop preceding the α -
29 helix C in FAK (C456-C459) but is not present in PYK2, we ran simulations twice, with and without the
30 corresponding disulphide bridge. The simulations, however, showed only minor differences in the protein
31 dynamics for the structures with and without disulphide bridges.

44 MD and τ RAMD simulations

45
46 The τ RAMD method for simulation of dissociation trajectories of protein ligand complexes and
47 computation of relative residence times has been reported elsewhere (Kokh et al., 2018), where the
48 method was assessed on 70 N-HSP90 ATP-pocket binding compounds, and we used the same method and
49 parameterization. Here, we will give a brief description of the procedure (a complete workflow is
50 illustrated in **Fig. S7** (Panel A was prepared using weblogo web server (Crooks et al., 2004)).

51
52 We employed the Gaff force field (Wang et al., 2004) for ligands and the Amber ff14 force field (Maier et
53 al., 2015) for the protein. RESP (Cornell et al., 2002) partial atomic charges for ligands were obtained using
54 molecular electrostatic potentials from ab initio quantum mechanical calculations performed at the HF
55 level with a 6-31G*(1d) basis set using the GAMESS software (Gordon and Schmidt, 2005).

1
2
3
4 First, the system was solvated in a periodic box of TIP3P water molecules (Jorgensen, 1983) with NaCl ion
5 concentration of 150mM. Then it was energy minimized, gradually heated and equilibrated stepwise with
6 decreasing harmonic restraints on all heavy atoms of the protein and ligand using the AMBER15 software
7 (Case et al., 2015). Then the system was run for 10 ns without restraints and the final snapshot was used
8 as an input for equilibration simulations carried out with the NAMD (Phillips et al., 2005) simulation
9 software. The equilibration was performed in the NPT ensemble using the Langevin and Nosé–Hoover
10 methods for the temperature (300K) and pressure (1 atm) control, respectively. At least four replicas of
11 equilibration simulations (20ns each) were prepared for each ligand.
12
13
14
15
16
17
18

19 The last snapshot of each replica was used to simulate ligand dissociation. For this, the RAMD method
20 (Lüdemann et al., 2000) was applied, where an additional force with a magnitude of 13 kcal/molÅ and a
21 random direction was applied to the center of mass of the ligand in MD simulations. Every 100 fs, the force
22 direction was changed randomly if the ligand center of mass did not move further than a threshold of
23 0.025Å and was retained otherwise. Simulations were stopped if the ligand center of mass moved further
24 than 30 Å from the original position. At least 10 RAMD dissociation trajectories were generated starting
25 with each equilibration replica. The times required for ligand dissociation in each trajectory were stored
26 and used for computation of the relative residence times as described in (Kokh et al., 2018) and illustrated
27 in **Fig. S7**.
28
29
30
31
32
33
34

35 Additionally, we repeated computations with a random force magnitude of 8 kcal/molÅ for the fast
36 dissociating compounds only ($k_{\text{off}} > 1.e-3 \text{ s}^{-1}$, compounds **2, 6, 7, 8, 9** and **12** with FAK and all compounds
37 with PYK2) in order to sample the egress process more slowly. However, we did not obtain a significant
38 improvement in the correlation with SPR data.
39
40
41
42

43 Conventional MD simulations for the apo-protein structures were performed using the same procedure
44 and parameters as described above for the equilibration step of the τ RAMD workflow. For each protein,
45 three 500 ns trajectories were simulated.
46
47
48

49 [Analysis of MD trajectories](#)

50 To analyse the protein-ligand interactions in the complexes, we computed protein-ligand interaction
51 fingerprints, IFP, for the last 500 frames of each compound and equilibration trajectory using the MD-IFP
52 tools (Kokh et al., 2020). In this approach, the IFP include hydrophobic interactions, salt-links, hydrogen
53 bonds, halogen bonds, aromatic interactions and water-mediated protein-ligand bridges, as well as all
54 unspecific contacts within a threshold of 5Å (aromatic interactions and salt bridges make very minor
55 contributions and, therefore, are not presented in plots). From these data, the occurrence of each type of
56
57
58
59
60
61
62
63
64
65

1
2
3
4 interaction was obtained for each compound and the binding site protein residues. For the computation
5 of BSA, the occurrence of unspecific protein-ligand contacts was employed.
6

7 8 Quantification and statistical analysis 9

10 *Surface-Plasmon-Resonance Data*

11 Data from at least n=5 individual experiments are reported as k_{on} , k_{off} , K_D average \pm SD. For analysis, the
12 Biacore 4000 Evaluation software, version 1.1 was used for solvent correction and double-referenced
13 association and dissociation phase data fitting to a simple 1:1 interaction model with mass transport
14 limitations.
15
16
17
18

19 *NanoBRET Data*

20 Data from at least n=3 individual experiments are reported as K_i , k_{obs} average \pm SEM. Analysis for IC_{50}
21 determination was performed using GraphPad Prism 8 software using a 4-parameter curve fit with the
22 following equation: $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{Log}IC_{50} - X) * \text{HillSlope}))}$. IC_{50} s were then converted
23 to $K_{i,obs}$ using the Cheng-Prusoff-Relation (Cheng and Prusoff, 1973) taking the tracer parameters and tracer
24 concentration into account. Analysis for k_{obs} determination was performed using GraphPad Prism 8
25 software using a one-phase association fit with the following equation: $Y = Y_0 + (\text{Plateau} - Y_0) * (1 - \exp(-K * x))$.
26
27
28
29
30
31
32




33 34 References

35
36 Allen, J.G., Lee, M.R., Han, C.-Y.E., Scherrer, J., Flynn, S., Boucher, C., Zhao, H., O'Connor, A.B., Roveto, P.,
37 Bauer, D., *et al.* (2009). Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2)
38 with osteogenic activity in osteoblast cells. *Bioorganic & medicinal chemistry letters* *19*, 4924–4928.
39 Arcari, J.T., Bhattacharya, S.K., Brosius, A.D., Luzzio, M.J., Nelson, K.L., Pan, G., Southers Jr., J.A., Wishka,
40 D.G., and Xiao, J. (2006). Pyrimidine derivatives for the treatment of abnormal cell growth
41 (WO2007072158A2).
42 Avraham, H., Park, S.-Y., Schinkmann, K., and Avraham, S. (2000). RAFTK/Pyk2-mediated cellular signalling.
43 *Cellular Signalling* *12*, 123–133.
44 Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Roversi, P., Sharff, A., Smart, O.,
45 and Vonrhein, C. (2016). BUSTER (Global Phasing Ltd., Cambridge, UK). Version XYZ.
46 Buckbinder, L., Crawford, D.T., Qi, H., Ke, H.Z., Olson, L.M., Long, K.R., Bonnette, P.C., Baumann, A.P.,
47 Hambor, J.E., and Grasser, W.A. (2007). Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and
48 bone formation, and offers an anabolic treatment approach for osteoporosis. *Proceedings of the National*
49 *Academy of Sciences* *104*, 10619-10624.
50 Case, D., Berryman, J., Betz, R., Cerutti, D., Cheatham Iii, T., Darden, T., Duke, R., Giese, T., Gohlke, H., and
51 Goetz, A. (2015). AMBER 2015.
52 Cheng, Y.-C., and Prusoff, W.H. (1973). Relationship between the inhibition constant (K_1) and the
53 concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction. *Biochemical*
54 *pharmacology* *22*, 3099-3108.
55 Copeland, R.A. (2016). The drug–target residence time model: A 10-year retrospective. *Nature Reviews*
56 *Drug Discovery* *15*, 87.
57
58
59
60
61
62
63
64
65


1
2
3
4 Cornell, W.D., Cieplak, P., Bayly, C.I., and Kollman, P.A. (2002). Application of RESP charges to calculate
5 conformational energies, hydrogen bond energies, and free energies of solvation. *Journal of the American*
6 *Chemical Society* *115*, 9620-9631.
7 Crooks, G.E., Hon, G., Chandonia, J.-M., and Brenner, S.E. (2004). WebLogo: a sequence logo generator.
8 *Genome research* *14*, 1188-1190.
9 Dolinsky, T.J., Czodrowski, P., Li, H., Nielsen, J.E., Jensen, J.H., Klebe, G., and Baker, N.A. (2007). PDB2PQR:
10 expanding and upgrading automated preparation of biomolecular structures for molecular simulations.
11 *Nucleic acids research* *35*, W522-W525.
12 Dolinsky, T.J., Nielsen, J.E., McCammon, J.A., and Baker, N.A. (2004). PDB2PQR: an automated pipeline for
13 the setup of Poisson–Boltzmann electrostatics calculations. *Nucleic acids research* *32*, W665-W667.
14 Emsley, P. (2017). Tools for ligand validation in Coot. *Acta Crystallographica Section D: Structural Biology*
15 *73*, 203-210.
16 Fan, H., and Guan, J.-L. (2011). Compensatory function of Pyk2 protein in the promotion of focal adhesion
17 kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. *The Journal of*
18 *biological chemistry* *286*, 18573–18582.
19 Farand, J., Mai, N., Chandrasekhar, J., Newby, Z.E., Van Veldhuizen, J., Loyer-Drew, J., Venkataramani, C.,
20 Guerrero, J., Kwok, A., Li, N., *et al.* (2016). Selectivity switch between FAK and Pyk2: Macrocyclization of
21 FAK inhibitors improves Pyk2 potency. *Bioorg Med Chem Lett* *26*, 5926-5930.
22 Gordon, M.S., and Schmidt, M.W. (2005). Advances in electronic structure theory: GAMESS a decade later.
23 In *Theory and applications of computational chemistry* (Elsevier), pp. 1167-1189.
24 Han, S., Mistry, A., Chang, J.S., Cunningham, D., Griffor, M., Bonnette, P.C., Wang, H., Chrnyk, B.A.,
25 Aspnes, G.E., Walker, D.P., *et al.* (2009). Structural characterization of proline-rich tyrosine kinase 2 (PYK2)
26 reveals a unique (DFG-out) conformation and enables inhibitor design. *J Biol Chem* *284*, 13193-13201.
27 Heinrich, T., Seenisamy, J., Emmanuvel, L., Kulkarni, S.S., Bomke, J., Rohdich, F., Greiner, H., Esdar, C., Krier,
28 M., Gradler, U., *et al.* (2013). Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and
29 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors. *J Med Chem* *56*, 1160-1170.
30 Jones, S., Shapiro, G., Bendell, J., Chen, E., Bedard, P., Cleary, J., Pandya, S., Pierce, K., Houk, B., and Hosea,
31 N. (2011). Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in
32 patients with advanced solid tumors. *Journal of clinical oncology* *29*, 3002-3002.
33 Jorgensen, W. (1983). *J. Am. Chem. Soc.* *106* (1984) 6638. WL Jorgensen, J. Chandrasekhar, JD Madura, RW
34 Impey and ML Klein. *J Chem Phys* *79*, 0.
35 Kabsch, W. (2010). Xds. *Acta Crystallographica Section D: Biological Crystallography* *66*, 125-132.
36 Kath, J.C., and Luzzio, M.J. (2003). Pyrimidine derivatives for the treatment of abnormal cell growth
37 (WO2004056786A2).
38 Kokh, D.B., Amaral, M., Bomke, J., Grädler, U., Musil, D., Buchstaller, H.-P., Dreyer, M.K., Frech, M.,
39 Lowinski, M., Vallee, F., *et al.* (2018). Estimation of Drug-Target Residence Times by τ -Random Acceleration
40 Molecular Dynamics Simulations. *Journal of chemical theory and computation* *14*, 3859–3869.
41 Kokh, D.B., Doser, B., Richter, S., Ormersbach, F., Cheng, X., and Wade, R.C. (2020). A Workflow for
42 Exploring Ligand Dissociation from a Macromolecule: Efficient Random Acceleration Molecular Dynamics
43 Simulation and Interaction Fingerprints Analysis of Ligand Trajectories. *J Chem Phys* *153*.
44 Krissinel, E., and Henrick, K. (2007). Inference of macromolecular assemblies from crystalline state. *Journal*
45 *of molecular biology* *372*, 774-797.
46 Lietha, D., and Eck, M.J. (2008). Crystal structures of the FAK kinase in complex with TAE226 and related
47 bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. *PLoS One* *3*, e3800.
48 Lipinski, C.A., and Loftus, J.C. (2010). Targeting Pyk2 for therapeutic intervention. *Expert opinion on*
49 *therapeutic targets* *14*, 95-108.
50 López-Blanco, J.R., Canosa-Valls, A.J., Li, Y., and Chacón, P. (2016). RCD+: Fast loop modeling server. *Nucleic*
51 *acids research* *44*, W395-W400.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Lüdemann, S.K., Lounnas, V., and Wade, R.C. (2000). How do substrates enter and products exit the buried
5 active site of cytochrome P450cam? 2. Steered molecular dynamics and adiabatic mapping of substrate
6 pathways. *Journal of molecular biology* 303, 813-830.
7
8 Luzzio, M.J., Autry, C.L., Bhattacharya, S.K., Freeman-Cook, K.D., Hayward, M.M., Hulford, C.A., Nelson,
9 K.L., Xiao, J., and Zhao, X. (2008). Sulfonyl amide derivatives for the treatment of abnormal cell growth
10 (WO2008129380A1).
11 Lv, P.C., Jiang, A.Q., Zhang, W.M., and Zhu, H.L. (2018). FAK inhibitors in Cancer, a patent review. *Expert*
12 *Opin Ther Pat* 28, 139-145.
13
14 Maier, J.A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K.E., and Simmerling, C. (2015). ff14SB:
15 improving the accuracy of protein side chain and backbone parameters from ff99SB. *Journal of chemical*
16 *theory and computation* 11, 3696-3713.
17
18 Marks, C., Nowak, J., Klostermann, S., Georges, G., Dunbar, J., Shi, J., Kelm, S., and Deane, C.M. (2017).
19 Sphinx: merging knowledge-based and ab initio approaches to improve protein loop prediction.
20 *Bioinformatics* 33, 1346-1353.
21
22 Matsuhisa, A., Kinoyama, I., Toyoshima, A., Nakahara, T., Takeuchi, M., and Okada, M. (2001). Fused
23 imidazolium derivatives (US20030114508A1).
24
25 Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R.D., Kale, L., and
26 Schulten, K. (2005). Scalable molecular dynamics with NAMD. *Journal of computational chemistry* 26,
27 1781-1802.
28
29 Robers, M.B., Dart, M.L., Woodroffe, C.C., Zimprich, C.A., Kirkland, T.A., Machleidt, T., Kupcho, K.R., Levin,
30 S., Hartnett, J.R., Zimmerman, K., *et al.* (2015). Target engagement and drug residence time can be
31 observed in living cells with BRET. *Nature communications* 6, 10091.
32
33 Roberts, W.G., Ung, E., Whalen, P., Cooper, B., Hulford, C., Autry, C., Richter, D., Emerson, E., Lin, J., Kath,
34 J., *et al.* (2008). Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-
35 562,271. *Cancer Res* 68, 1935-1944.
36
37 Röhm, S., Berger, B.-T., Schröder, M., Chaikuad, A., Winkel, R., Hekking, K.F., Benningshof, J.J., Müller, G.,
38 Tesch, R., and Kudolo, M. (2019). Fast Iterative Synthetic Approach toward Identification of Novel Highly
39 Selective p38 MAP Kinase Inhibitors. *Journal of medicinal chemistry* 62, 10757-10782.
40
41 Schlaepfer, D.D., Hauck, C.R., and Sieg, D.J. (1999). Signaling through focal adhesion kinase. *Progress in*
42 *biophysics and molecular biology* 71, 435-478.
43
44 Schuetz, D.A., Witte, W.E.A.d., Wong, Y.C., Knasmueller, B., Richter, L., Kokh, D.B., Sadiq, S.K., Bosma, R.,
45 Nederpelt, I., and Heitman, L.H. (2017). Kinetics for Drug Discovery: An industry-driven effort to target
46 drug residence time. *Drug Discovery Today* 22, 896-911.
47
48 Slack-Davis, J.K., Martin, K.H., Tilghman, R.W., Iwanicki, M., Ung, E.J., Autry, C., Luzzio, M.J., Cooper, B.,
49 Kath, J.C., Roberts, W.G., *et al.* (2007). Cellular characterization of a novel focal adhesion kinase inhibitor.
50 *J Biol Chem* 282, 14845-14852.
51
52 Tai, Y.-L., Chen, L.-C., and Shen, T.-L. (2015). Emerging roles of focal adhesion kinase in cancer. *BioMed*
53 *research international* 2015, 690690.
54
55 Trott, O., and Olson, A.J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new
56 scoring function, efficient optimization, and multithreading. *Journal of computational chemistry* 31, 455-
57 461.
58
59 Tse, K.W.K., Lin, K.B.L., Dang-Lawson, M., Guzman-Perez, A., Aspnes, G.E., Buckbinder, L., and Gold, M.R.
60 (2012). Small molecule inhibitors of the Pyk2 and FAK kinases modulate chemoattractant-induced
61 migration, adhesion and Akt activation in follicular and marginal zone B cells. *Cellular immunology* 275,
62 47-54.
63
64 Vasta, J.D., Corona, C.R., Wilkinson, J., Zimprich, C.A., Hartnett, J.R., Ingold, M.R., Zimmerman, K.,
65 Machleidt, T., Kirkland, T.A., Huwiler, K.G., *et al.* (2018). Quantitative, Wide-Spectrum Kinase Profiling in
Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. *Cell Chem Biol* 25, 206-214 e211.


1
2
3
4 Vriend, G. (1990). WHAT IF: a molecular modeling and drug design program. *Journal of molecular graphics*
5 *8*, 52-56.
6 Walker, D.P., Bi, F.C., Kalgutkar, A.S., Bauman, J.N., Zhao, S.X., Soglia, J.R., Aspnes, G.E., Kung, D.W., Klug-
7 McLeod, J., Zawistoski, M.P., *et al.* (2008). Trifluoromethylpyrimidine-based inhibitors of proline-rich
8 tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive
9 metabolite formation. *Bioorg Med Chem Lett* *18*, 6071-6077.
10 Walker, D.P., Zawistoski, M.P., McGlynn, M.A., Li, J.-C., Kung, D.W., Bonnette, P.C., Baumann, A.,
11 Buckbinder, L., Houser, J.A., and Boer, J. (2009). Sulfoximine-substituted trifluoromethylpyrimidine
12 analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity. *Bioorganic &*
13 *medicinal chemistry letters* *19*, 3253-3258.
14 Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A., and Case, D.A. (2004). Development and testing of a
15 general amber force field. *Journal of computational chemistry* *25*, 1157-1174.
16 Wendt, M.K., Schiemann, B.J., Parvani, J.G., Lee, Y.-H., Kang, Y., and Schiemann, W.P. (2013). TGF- β
17 stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for
18 metastatic outgrowth of breast cancer. *Oncogene* *32*, 2005–2015.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65






B





C











KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and Virus Strains		
<i>Escherichia coli</i> Rosetta™ 2(DE3)	Novagen	Cat#71400
Chemicals, Peptides, and Recombinant Proteins		
1 – PF-562271	This study	Roberts et al., 2008 Arcari et al., 2006
2	This study	Matsuhisa et al., 2001
3	This study	Arcari et al., 2006
4	This study	Arcari et al., 2006
5 – PF-573228	This study	Slack-Davis et al., 2007
6	This study	Arcari et al., 2006
7	This study	n/a
8	This study	Arcari et al., 2006
9	This study	n/a
10 – PF-431396	This study	Buckbinder et al., 2007
11 – PF8554878 (defactinib)	This study	Jones et al., 2011
12 – PF-719	This study	Tse et al., 2012
Gibco™ DMEM	Invitrogen	Cat# 11960044
Gibco™ Heat inactivated FBS	Invitrogen	Cat#10500064
Gibco™ penicillin-streptavidin antibiotic	Invitrogen	Cat#15070063
Gibco™ OPTI-MEM	Invitrogen	Cat# 11058021
HerclII polymerase kit	Agilent	Cat# 600675
ATP	Sigma Aldrich	Cat# A9187-100MG
Magnesium formate dihydrate	Molecular Dimension	Cat# MD2-100-48
PEG3350	Molecular Dimension	Cat# MD2-100-9
Recombinant FAK (amino acid 410-689 with P410G mutation)	Instituto de Biologia Experimental e Tecnológica	n/a
Recombinant PYK2 (amino acid 420-691)	This study	n/a
Critical Commercial Assays		
Surface Plasmon Resonance CM5 kit	GE HealthCare	Cat# 29104988
NanoBRET Target engagement K5 kit	Promega	Cat# N2500
Deposited Data		
FAK in complex with 1	Roberts et al., 2008	pdb id: 3bz3
PYK2 in complex with 1	Farand et al., 2016	pdb id: 5tob
PYK2 in complex with 10	Han et al., 2009	pdb id: 3fzr
PYK2 in complex with 12	Walker et al., 2009	pdb id: 3h3c
FAK in complex with 2	This study	pdb id: 6yt6
FAK in complex with 3	This study	pdb id: 6yxv
FAK in complex with 4	This study	pdb id: 6yq1
FAK in complex with 5	This study	pdb id: 6yoj
FAK in complex with 8	This study	pdb id: 6yvs
FAK in complex with 10	This study	pdb id: 6yr9
Experimental Models: Cell Lines		

HEK293T	ATCC	Cat# CRL3216™
Oligonucleotides		
Mutagenesis primer pairs are listed in Table S4	Eurofins	https://www.eurofins.com/
Recombinant DNA		
FAK	Merck KgaA	n/a
PYK2	Merck KgaA	n/a
NLuc-FAK	Promega	Cat# NV1921
PYK2-NLuc	Promega	Cat# NV1931
NLuc-FAK-R426S	This study	n/a
NLuc-FAK-R426A	This study	n/a
NLuc-FAK-L567A	This study	n/a
NLuc-FAK-E506Q	This study	n/a
NLuc-FAK-E506I	This study	n/a
NLuc-FAK-E430S	This study	n/a
NLuc-FAK-E430Q	This study	n/a
NLuc-FAK-Y576F+Y577F	This study	n/a
PYK2-F435R-NLuc	This study	n/a
PYK2-E474Q-NLuc	This study	n/a
PYK2-F435Q-NLuc	This study	n/a
PYK2-Y579F+Y580F-NLuc	This study	n/a
Software and Algorithms		
XDS	Kabsch, 2010	http://xds.mpimf-heidelberg.mpg.de/
PISA web server	Krissinel and Henrick 2007	https://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver
BUSTER	Bricogne et al., 2016	https://www.globalphasing.com/buster/
COOT	Emsley, 2017	https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/
Prism	Graphpad	https://www.graphpad.com/scientific-software/prism/
WHATIF web server	Vriend, 1990	https://swift.cmbi.umcn.nl/servers/html/index.html
Pdb2pqr web server	Dolinsky et al., 2007	http://server.polisso.nboltzmann.org/
AutoDock Vina	Trott and Olson, 2010	http://vina.scripps.edu/
Sphinx web server	Marks et al., 2017	https://pypi.org/project/sphinx-server/
GAMMESS ab initio quantum chemistry package	Gordon and Schmidt, 2005	https://www.msg.chem.iastate.edu/gamess/

AMBER15 MD simulation software	Case et al., 2015	https://ambermd.org/
NAMD MD simulation software	Phillips et al., 2005	https://www.ks.uiuc.edu/Research/namd/
RAMD tcl script	Lüdemann et al., 2000	https://www.hits.org/downloads/ramd/
MD-IFP Python tools	Kokh et al., 2020	https://github.com/HITS-MCM/MD-IFP
RCD+ web server	López-Blanco et al., 2016	http://rcd.chaconlab.org/
WebLogo web Server	Crooks et al., 2004	https://weblogo.berkeley.edu/

Supplementary Information

Table of contents:

1. Fig. S1: Sequence alignment of FAK and PYK2, related to Fig. 1.
2. Table S1: Assessment of structural data on the protein-ligand interface in FAK to various inhibitors and PYK2 to compound 1 (PDB 5tob), related to Fig. 1 and Fig. 2.
3. Fig. S2: Comparison of the binding mode of PF-562271 and TAE226, related to Fig. 2.
4. Fig. S3: Kinetic profiles for the series investigated for FAK and PYK2, related to Table 1 and Fig. 2.
5. Fig. S4: Dependence of computed residence times on the modelling of complexes of compounds 1 and 3 bound to PYK2 and compound 9 bound to FAK, related to Fig. 4.
6. Table S2: Data collection and refinement statistics for FAK structures, related to Fig. 2 and Fig. 3.
7. Fig. S5: Cellular affinity and kinetics for FAK and PYK2 as well as their respective mutants on the series investigated in this study, related to Fig. 5 and Fig. 6.
8. Table S3: NanOBRET target engagement and wash-out data for FAK and PYK2 and their respective mutants investigated in this study, related to Fig. 5 and Fig. 6.
9. Fig. S6: Comparison of protein structural variations along MD simulation trajectories, related to Fig. 6.
10. Fig. S7: Illustration of the tRAMD workflow, related to STAR Methods Section.
11. Table S4: Mutagenesis primer pairs for generation of mutated NanOBRET plasmids, related to STAR Methods Section.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Supplementary figure S1

```

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

```

FAK 422 -ELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKL
 PYK2 425 VVLMRI~~LGEG~~FFGEVYEGVYTNHKGEKINVAVKTCCKDCTLDNKEKFMSEAVIMKNLDHPHIVKL
 . :*** **:***:***: . . . : **:*:***: . . :***:***: *:::*****

FAK 487 IGVITENPVWII~~MEICTLGE~~FLRSFLQVRKYSLDLASLILYAYQLSTALAYLESKR~~FVHRDIAARN~~
 PYK2 490 IGIIEEPTWII~~MEIYPYGE~~LGHYLERNKNSLKVLT~~LVLSLQICKAMAYLESINCVHRDIAVRN~~
 : * *:*.*:*** . *** :*: . * **.: :*:***: *:.*.***: . *****.*

FAK 552 ~~LVSSNDCVKLGD~~FG~~LS~~RYMEDSTYYKASKGKLP~~IKW~~MAPESINFRFRFTSASDVVMFVCMWEIL
 PYK2 555 ~~ILVASPECVKLG~~DFGLSRYIEDEDYKASVTRL~~PIKW~~MSPESINFRFRFTTASDVVMFAVCMWEIL
 :*:* :*****:***:***: * ***** :*****:*****:*****:*****.*

FAK 617 MHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTIL
 PYK2 620 SFGKQPF~~FWLENKDVIGVLEK~~GDRLPKPDLCPPVLYTLMTRCWDYDPSDRPRFTELVC~~SLSDVY~~
 .* :** :*:***: :*:***: * ***.***:***:*** ***** ***** ..** :

Fig. S1: Sequence alignment of FAK and PYK2 (ClustalW), related to Fig. 1. Structural elements are named according to the KLIFS (Kooistra et al., 2016)-assessment of FAK PDB 3bz3 (Roberts et al., 2008) and PYK2 PDB 5tob (Farand et al., 2016). Beta-sheets are labelled with Roman italic numbers, alpha-helices are underlined. g.l=glycine-rich-loop, b.l=b-loop, G=Gatekeeper, H=Hinge, lin=linker, c.l=catalytic-loop, a.l=activation loop. Residues involved in interactions with PF-562271 (**1**) in the above mentioned PDBs are shown in red and interesting residues or differences in sequence are labelled with a black rectangle.

Supplementary table S1

Table S1: Assessment of structural data on the protein-ligand interface in FAK to various inhibitors and PYK2 to compound 1 (PDB 5tob), related to Fig. 1 and Fig. 2. The Accessible Surface Area (ASA) and the Buried Surface Area (BSA) in the crystal structures (from the PISA database (Krissinel and Henrick, 2007)) are given and the presence of the protein residue-ligand contact (PLC) in MD simulations is indicated. A PLC value of 1.0 means that the contact was always present within a threshold distance of 5Å. Yellow colour indicates a contact and blue colour indicates no contact.

PDB	3bz3		6yt6		6yvz		6wt1		6yvj		6yvs		6yvj		6yvs		6yvj		5tob	
	Gpd	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK	FAK
FAK Residue	ASA	BSA	ASA	BSA	ASA	BSA	ASA	BSA	ASA	BSA	ASA	BSA	ASA	BSA	ASA	BSA	ASA	BSA	ASA	BSA
1	A:ARG 550	76.79	13.19	90.27	11.1	80.69	12.5	74.26	11.72	99.22	14.48	86.28	6.24	69.28	11.3	A:ARG 553	65.60	8.8	ASA	BSA
2	A:ASN 551	14.68	9.74	13.27	3.4	17.02	12.3	15.73	11.03	14.40	9.17	12.57	0.00	17.99	11.1	A:ASN 554	29.90	11.4	ASA	BSA
3	A:VAL 552	1.33	0.00	1.01	0.00	0.67	0.00	1.01	0.00	1.43	0.14	0.34	0.00	1.51	0.00		0.00	0.00	0.00	0.00
4	A:LEU 553	46.04	46.04	43.32	43.3	48.66	48.6	45.78	45.78	52.82	52.82	50.92	48.08	43.93	43.9	A:LEU 556	40.33	40.3	ASA	BSA
5		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00	0.00
6	A:SRR 555	26.93	0.00	32.87	0.00	30.52	0.00	28.56	0.00	34.08	0.00	27.78	0.00	25.08	0.00	A:ALA 558	27.84	0.00	ASA	BSA
7	A:SRR 556	43.92	0.00	40.01	0.00	42.72	0.00	43.53	0.00	44.53	0.00	41.63	0.00	42.68	0.00	A:SRR 559	41.28	0.00	ASA	BSA
8	A:ASN 557	78.84	0.00	83.56	0.00	82.56	0.00	83.24	0.00	84.46	0.00	100.18	0.00	81.05	0.00	A:PRO 560	63.09	0.00	ASA	BSA
9	A:ASP 558	85.47	0.00	92.26	0.00	92.80	0.00	93.33	0.00	98.27	0.00	92.10	0.00	92.85	0.00	A:GLU 561	123.61	0.00	ASA	BSA
10	A:CYS 559	24.41	0.00	25.53	0.00	25.08	0.00	25.06	0.00	25.66	0.00	25.59	0.00	26.35	0.00	A:CYS 562	28.91	0.00	ASA	BSA
11		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00	0.00
12	A:IYS 561	23.93	0.00	24.20	0.00	23.67	0.00	21.76	0.00	19.65	0.00	24.94	0.00	19.19	0.00	A:IYS 564	23.96	0.00	ASA	BSA
13	A:LEU 562	3.19	0.00	2.51	0.00	2.51	0.00	2.31	0.00	2.53	0.00	1.02	0.00	3.18	0.00	A:LEU 565	0.50	0.00	ASA	BSA
14	A:GLY 563	3.60	3.19	8.03	7.7	4.91	4.5	6.33	5.18	3.65	3.35	20.73	9.8	5.82	4.5	A:GLY 566	2.37	1.51	ASA	BSA
15	A:ASP 564	8.84	8.22	36.44	14.9	9.12	8.8	9.98	9.49	8.58	8.08	48.64	0.00	10.11	9.6	A:ASP 567	39.44	10.2	ASA	BSA
16	A:PHE 565	17.13	0.00	9.52	0.00	4.56	0.00	4.75	0.00	1.98	0.00	3.98	0.00	4.62	0.00	A:PHE 568	45.90	0.00	ASA	BSA
17	A:GLY 566	6.21	0.00	24.12	0.00	14.06	0.00	6.72	0.00	15.77	0.00	48.98	0.00	18.49	0.00	A:GLY 569	66.89	0.00	ASA	BSA
18	A:LEU 567	60.25	46.45	105.00	0.00	60.07	46.9	46.92	41.25	66.94	39.41	80.47	0.00	55.63	48.7		48.7	ASA	BSA	
19	A:SRR 568	5.53	1.43	84.16	0.00	2.52	1.00	2.27	1.85	6.59	2.18	17.85	0.00	6.83	1.1		1.1	ASA	BSA	

Supplementary figure S2




Fig. S2: Comparison of the binding mode of PF-562271 and TAE2226, related to Fig. 2. A) Chemical structures of TAE2226 (Lietha and Eck, 2008) and PF-562271 (Roberts et al., 2008) (**1**). **B)** Overlay of FAK bound to TAE2226 (red and blue, PDB 2jkk (Lietha and Eck, 2008)) and FAK in complex with PF562271 (**1**) (cyan and yellow, PDB 3bz3 (Roberts et al., 2008)). Compound structure was drawn using Biovia Draw 2017, models were depicted using PyMol 1.7.6.2.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Supplementary figure S3





Fig. S3: Kinetic profiles for the series investigated for FAK and PYK2, related to Table 1 and Fig. 2. A) SPR sensorgram for **10** and PYK2. **B)** SPR sensorgram for **10** and FAK. **C)** k_{on} - k_{off} -plot of the SPR-data for the series investigated in this study. FAK is depicted in black circles and PYK2 in red squares. The inhibitor number is indicated for each data point and data for FAK and PYK2 for each inhibitor are connected with a black line. SPR sensorgrams were depicted via the application software of the Biacore 4000 and figure C was created using GraphPad Prism 8.

Supplementary figure S4



1
2
3
4 **Fig. S4: Dependence of computed residence times on the modelling of complexes of compounds 1 and**
5 **3 bound to PYK2 and compound 9 bound to FAK, related to Fig. 4: (A)** Positions of F568 in MD simulations
6 starting from two different crystal structures of PYK2, PDB: 3FZ3 and 5TOB; although F568 is highly flexible
7 in the latter case, its general orientation is preserved as in the starting structure. **(B)** Comparison of the
8 binding site structures of FAK (grey) and “chimeric” PYK2 (beige) in complexes with compound **3** (carbon
9 atoms coloured green and yellow in the complexes with FAK and PYK2, respectively). **(C)** Relative residence
10 time computed for compound **3** from τ RAMD simulations (with a random force magnitude of 13 kcal/mol
11 Å) starting from the four different structures shown in (D). **(D)** The structures of the complexes with
12 compound **3**, were modelled by similarity to crystal structure PDB: 3FZ3, compound **1** (1) and by docking
13 (see Methods) using the crystal structures 3FZ3 (2), 5TOB (3), and the “chimeric” PYK2 structure with a
14 helical conformation of the DFG loop (4). The last snapshots from two MD equilibration runs are shown in
15 each image. **(E-F):** Equivalent plots for compound **1**: **(E)** The residence times obtained from τ RAMD
16 simulations with different initial positions for F568 (1- as in PDB ID: 3FZ3 and 2 – as in PDB ID: 5TOB); **(F)**
17 The corresponding equilibrated structures. **(G)** Computed residence times obtained from τ RAMD
18 simulations of compound **9** bound to FAK starting with the ligand docked to the loop conformation of the
19 DFG motif (the first and the second-ranked docking pose are denoted by 2 and 1, respectively) and to the
20 helical conformation of the DFG motif of FAK (the first and the second-ranked docking pose are denoted
21 by 4 and 3, respectively; the random force magnitude was 11 kcal/mol Å). The variation in k_{off} due to
22 different starting poses of the ligand or conformations of the protein is only about 2-3-fold for this
23 compound, which is in the range of uncertainty in the residence time computed in τ RAMD simulations.
24 Interestingly, short residence times were computed for the docked structure in which a hydrogen bond
25 with R426 was not possible due to the ligand orientation, whereas the position of the phenyl ring relative
26 to the hydrophobic residue L567 seemed to have less effect on the residence time. **(H)** Docking poses after
27 equilibration (four replicas) corresponding to the residence times shown in **(G)**; ligand (green carbons)
28 positions relative to R426 (blue nitrogen atoms) in FAK (grey cartoon) are highlighted in the insets. A frame
29 with a different binding site and ligand conformation is highlighted in (3) in light-blue (protein) and cyan
30 (ligand). The mutual dependence of the positions of the ligand phenyl ring, L570 and the first β -sheet can
31 be observed. Models were depicted using PyMol 1.7.6.2 and figures C, E, and G were created using Python
32 (library Matplotlib).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Supplementary table S2

Table S2: Data collection and refinement statistics for FAK structures, related to Fig. 2 and Fig. 3.

Structure	2	3	4	5 (PF-573228)	8	10 (PF431396)	12 (PF-719)
Data Collection							
Space Group	<i>P1</i>	<i>C2</i>	<i>C2</i>	<i>P212121</i>	<i>C2</i>	<i>C2</i>	<i>C2</i>
cell parameters (Å)	45.35, 51.35, 67.07	118.05, 77.13, 174.93	112.53, 75.75, 173.27	42.53, 48.40, 129.33	114.17, 76.08, 172.85	110.22 74.54 172.55	113.97, 75.86, 172.64
cell angles (°)	99.36, 102.89, 92.51	90.00, 101.34, 90.00	90.00, 102.37, 90.00	90.00, 90.00, 90.00	90.00, 102.53, 90.00	90.00 103.11 90.00	90.00, 102.66, 90.00
Molecules/AU	2	4	4	1	4	4	4
Resolution (Å) ^a	64.35-1.54 (1.64-1.54)	171.52-2.30 (2.57-2.30)	62.37-1.78 (2.02-1.78)	45.33-1.36 (1.44-1.36)	84..37-1.81 (2.035-1.81)	84.03-1.93 (2.17-1.93)	56.49-1.92 (1.98-1.92)
Unique reflections	56803	44522	82421	47762	81043	48069	88953
Completeness (%) ^a	82.7 (64.9)	92.6 (64.7)	93.2 (67.9)	89.8 (51.7)	92.0 (69.5)	88.0 (72.8)	85.6 (71.7)
Multiplicity ^a	1.9 (1.9)	3.3 (3.4)	4.1 (3.8)	7.6 (5.1)	3.4 (3.4)	3.4 (3.5)	4.9 (5.1)
<i>R</i> _{pim} (%) ^a	2.8 (57.0)	3.5 (42.7)	4.2 (34.4)	3.2 (58.1)	3.5 (39.2)	3.4 (40.7)	3.5 (36.6)
CC(1/2) ^a	0.999 (0.522)	0.999 (0.710)	0.998 (0.786)	0.999 (0.387)	0.999 (0.728)	0.999 (0.670)	0.997 (^0.730)
Mean <i>I</i> / <i>σ</i> (<i>I</i>) ^a	10.5 (1.2)	12.3 (1.9)	10.5 (2.2)	16.0 (1.2)	11.7 (1.8)	14.3 (1.9)	11.9 (1.7)
Refinement							
<i>R</i> _{works} (%) ^b	19.0	23.2	18.3	17.1	19.2	19.2	21.4
<i>R</i> _{free} (%) ^b	21.2	20.2	21.4	19.8	21.5	21.8	23.5
No. of atoms	4553	8654	9648	2479	8983	8664	8960
Protein ^c	4125	8387	8576	2081	8244	8349	8323
Water	360	138	922	364	622	175	508
Ligands	67	124	144	34	116	140	124
other solvent molecules	1	5	6	0	5	0	5
RMSD bonds (Å)	0.008	0.008	0.008	0.008	0.008	0.008	0.008
RMSD angles (°)	0.88	0.98	0.89	0.95	0.85	0.86	0.91
Mean <i>B</i> (Å ²)	32.9	60.78S	31.0	17.0	39.2	38.4	39.2
Ramachandran (%)							
Favoured	92	93	92	94	93	93	93
Allowed	8	7	8	6	6	7	7
Outliers	0	0	0	0	0.1	0.1	0
PDB entry	6YT6	6YXV	6YQ1	6YOJ	6YVS	6YR9	6YVY

Supplementary figure S5




Fig. S5: Cellular affinity and kinetics for FAK and PYK2 as well as their respective mutants on the series investigated in this study, related to Fig. 5 and Fig. 6. Compound numbers and targets are indicated in the figure legends. NanoBRET tracer potencies (A) and tracer kinetics (B) were determined in intact cells for FAK and PYK2, respectively. The kinetic assay uses a wash-out technique where dissociating inhibitor is visualised by associating tracer molecule. Inhibitor potency (C) and kinetics (D) were determined on FAK and PYK2, respectively. The inhibitor potency was also assessed for FAK (E) and PYK2 (F) mutants as well as the respective binding kinetics (G and H). Figures were created using GraphPad Prism 8.

Supplementary table S3

Table S3: NanoBRET target engagement and wash-out data for FAK and PYK2 and their respective mutants investigated in this study, related to Fig. 5 and Fig. 6. The *in cellulo* potency and kinetics of a series of inhibitors based on **1** were determined using NanoBRET target engagement and wash-out assays. $K_{i, app}$ = Cheng-Prusoff corrected Inhibitory Concentration for 50% (IC_{50}) observed under cellular conditions, k_{obs} = observed kinetic constant, $t_{1/2}$ = half-life calculated as $\ln(2)/k_{obs}$. For the mutants, the fold-change to FAK and PYK2 wild type protein IC_{50} s for the FAK and PYK2 mutants, respectively, were calculated (mutant K_i /WT K_i). Blue indicates a fold-change of more than 2, indicating the potency decreased for the mutant in comparison to the WT while red indicates a fold change of less than 0.5, indicating the potency increased for the mutant compared to the WT. Similarly, the fold-change to FAK and PYK2 wild type protein k_{obs} for the FAK and PYK2 mutants, respectively, were calculated (mutant k_{obs} /WT k_{obs}). Blue indicates a fold-change of more than 2, indicating the k_{obs} increased for the mutant in comparison to the WT (overall faster kinetics). A fold change of less than 0.5 is marked in red, indicating the k_{obs} decreased for the mutant compared to the WT (overall slower kinetics).

Target	Data	1	2	3	4	5	8	10	11	12
FAK	K_i , [M]	(9.3±1.2)E-09	(4.1±1.3)E-06	(1.2±0.1)E-08	(3.2±0.3)E-09	(1.1±0.1)E-08	(7.6±1.4)E-06	(8.7±1.0)E-10	(1.0±0.2)E-09	(7.8±0.3)E-06
	k_{obs} , [1/min]	(5.9±0.2)E-02	n.d.	(2.2±0.7)E-01	(4.0±0.8)E-02	(2.7±0.6)E-01	> 1	(1.2±0.8)E-02	(1.3±0.2)E-01	> 1
	$t_{1/2}$, [min]	11.8	n.d.	3.1	17.5	2.6	0.7	57.3	5.4	0.7
PYK2	K_i , [M]	(1.5±0.2)E-07	(2.3±0.4)E-05	(1.2±0.1)E-7	(8.4±0.7)E-08	(3.6±0.3)E-06	(2.6±1.2)E-05	(8.0±0.4)E-08	(6.3±1.1)E-07	(9.7±1.6)E-07
	k_{obs} , [1/min]	(5.1±3.0)E-01	n.d.	(6.3±5.3)E-01	(2.7±0.2)E-01	(7.3±3.9)E-01	> 1	(4.9±3.0)E-01	(5.5±2.2)E-01	(5.3±1.0)E-01
	$t_{1/2}$, [min]	1.4	n.d.	1.1	2.6	1.0	0.7	1.4	1.3	0.7
FAK(R426S)	K_i Ratio M/WT	1.0	n.d.	1.7	1.2	1.4	1.6	1.6	1.6	0.68
	k_{obs} Ratio M/WT	0.9	n.d.	0.8	13.2	0.7	1.0	1.0	0.8	1.0
FAK(R426A)	K_i Ratio M/WT	0.91	n.d.	1.4	1.0	1.2	1.2	1.3	1.7	1.6
	k_{obs} Ratio M/WT	1.0	n.d.	0.8	1.6	0.7	1.0	1.4	1.0	1.0
FAK(L567A)	K_i Ratio M/WT	13	n.d.	28	42	3.2	1.6	46	98	0.38
	k_{obs} Ratio M/WT	5.0	n.d.	3.2	7.9	0.7	0.6	22.7	6.0	0.6
FAK(E506Q)	K_i Ratio M/WT	1.6	n.d.	2.3	2.4	6.6	3.4	1.8	3.4	19
	k_{obs} Ratio M/WT	2.2	n.d.	2.5	2.1	1.1	1.0	1.9	3.8	1.0
FAK(E506I)	K_i Ratio M/WT	19	n.d.	2.1	1.5	1.9	2.0	2.3	2.2	0.00038
	k_{obs} Ratio M/WT	1.4	n.d.	1.7	1.6	3.0	1.0	1.1	2.1	1.0
FAK(E430S)	K_i Ratio M/WT	1.3	n.d.	2.0	1.4	1.3	2.5	1.6	1.8	3.4
	k_{obs} Ratio M/WT	0.9	n.d.	1.4	1.0	0.6	1.0	1.1	1.1	1.0
FAK(E430Q)	K_i Ratio M/WT	0.9	n.d.	1.9	1.3	1.2	1.5	1.5	1.4	0.65
	k_{obs} Ratio M/WT	0.8	n.d.	1.0	0.9	0.7	1.0	0.8	0.9	1.0
FAK(Y576F+Y577F)	K_i Ratio M/WT	1.0	n.d.	1.5	1.2	1.2	1.7	1.3	1.5	1.0
	k_{obs} Ratio M/WT	1.0	n.d.	1.1	1.0	0.5	1.0	1.2	0.7	1.0
PYK2(F435R)	K_i Ratio M/WT	1.8	n.d.	1.4	1.6	1.2	1.4	1.9	1.6	1.4
	k_{obs} Ratio M/WT	2.0	n.d.	1.6	3.8	1.4	1.0	2.0	1.8	1.9
PYK2(E474Q)	K_i Ratio M/WT	8.8	n.d.	5.1	6.2	2.1	4.9	5.4	3.1	9.5
	k_{obs} Ratio M/WT	0.2	n.d.	0.6	0.9	0.3	0.1	0.4	0.5	0.3
PYK2(F435Q)	K_i Ratio M/WT	1.4	n.d.	1.1	0.76	0.5	0.71	0.86	0.83	0.74
	k_{obs} Ratio M/WT	0.8	n.d.	0.8	1.3	1.1	0.9	1.1	1.4	1.6
PYK2(Y579F+Y580F)	K_i Ratio M/WT	1.1	n.d.	1.4	0.72	0.53	0.65	0.77	0.66	0.94
	k_{obs} Ratio M/WT	0.4	n.d.	0.3	0.8	0.4	0.3	0.4	0.5	0.3

Supplementary figure S6




Fig. S6: Comparison of protein structural variations along MD simulation trajectories, related to Fig. 6: (A-C) the unbound wild type PYK2 protein and the F435Q and F435A mutants (denoted F, by Q, and A, respectively), and (D-H) MD starting with the final structure (after 60ns simulation) of the FAK and “chimeric” PYK2 structure with the helical conformation of the DFG-motif. (A) Sequence alignment of the 1st beta-strand and the region around the P-loop in PYK2 and FAK with the residues that may affect protein flexibility highlighted in red and the corresponding amino acid occurrence in 100 tyrosine kinases; (B) RMSD of the residue 435 in the wild type and in F435Q and F435A mutants of PYK2; (C) Distance between the C-alpha atoms of residue 435 and three other phenylalanine residues (F436, F471 and F568) in the wild type PYK2 and F435Q and F435A mutants; (D) Change in the structure of PYK2 and FAK after equilibration, the RMSD is computed for the last snapshot relative to the first one and averaged over 4 trajectories. (E, F) - FAK (E) and PYK2 (F) structures before (light-grey and pink) and after 60ns equilibration (dark grey and wheat). (G, H) - Comparison of the structures of FAK and PYK2 (coloured in grey and beige, respectively) for two representative snapshots from the PYK2 and FAK trajectories in conventional MD simulations. Figure A was generated by WebLogo 322. Models were depicted using PyMol 1.7.6.2 and figure D created using Python (library Matplotlib).

Supplementary figure S7




Fig. S7: Illustration of the τ RAMD workflow, related to the STAR Methods Section: (A) schema that illustrates a workflow for simulation of the relative residence time of a single compound: final coordinates and velocities from several standard MD equilibration replicas are used as starting for RAMD dissociation simulations; the length of dissociation trajectories then is employed for an estimation of the relative residence times using a protocol illustrated in panels B-D; (B-D) procedure for computing relative residence times from the simulated dissociation times illustrated for two compounds (fast dissociating compound 3 – upper plot, and slow dissociating compound 1 – lower plot): (B) Cumulative histograms of dissociation times observed in 10 RAMD trajectories computed with a random force magnitude of 11 kcal/mol/Å for each of the four different starting replicas, generated from the four standard MD equilibration simulations. Simulations for each starting replica are shown in different colours; a dissociation time t , defined as the time when dissociation is observed in 50% of trajectories, is indicated by a vertical dashed line shown in the same colour scheme as the histogram; the horizontal dashed line indicates a threshold of 50%. (C) Distribution of dissociation times t obtained from bootstrapping of dissociation trajectories for each starting frame separately (80% of trajectories are selected in each bootstrap round to obtain t , 500 rounds are performed). (D) Box representation of distribution shown in fig.(B): boxes show the quartiles of the computed residence time distribution starting frame, while the whiskers extend to show the rest of the distribution; the orange line shows the mean value (τ_{RAMD} for a particular starting frame); the gray solid line indicates the mean of τ_{RAMD} for four frames, used as the final τ_{RAMD} value, and the gray dashed lines show the standard deviation of τ_{RAMD} . Figures were created using Python (library Matplotlib).

Table S4: Mutagenesis primer pairs for generation of mutated NanoBRET plasmids, related to the STAR Methods Section.

Reagent	Source	Identifier
Mutagenesis primer pair for NLuc-FAK-R426S CTTGGATCATGTATTGGAGAAGGCCAATTTGGAGATGTAC AATACATGATCCAAGTTCTATTCTTTCTCTTTGAATCTC	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for NLuc-FAK-R426A CTTGGAGCATGTATTGGAGAAGGCCAATTTGGAGATGTAC CAATACATGCTCCAAGTTCTATTCTTTCTCTTTGAATCTC	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for NLuc-FAK-L567A CTTTGGAGCATCCCGATATATGGAAGATAGTACTTACTAC TCGGGATGCTCCAAGTCTCCTAATTTTACACAATCATTG	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for NLuc-FAK-E506Q CTTGGACAGCTGAGGTCATTTTTGCAAGTAAGGAAATAC CCTCAGCTGTCCAAGTGTGCACAGCTCCATGATTATCCAG	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for NLuc-FAK-E506I CTTGAATTCTGAGGTCATTTTTGCAAGTAAGGAAATAC CCTCAGAATTCCAAGTGTGCACAGCTCCATGATTATCCAG	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for NLuc-FAK-E430S GTATTGGAAGCGGCCAATTTGGAGATGTACATCAAGGC TTGGCCGCTTCCAATACATCGTCCAAGTTCTATTCTTTC	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for NLuc-FAK-E430Q GTATTGGACAGGGCCAATTTGGAGATGTACATCAAGGC TTGGCCCTGTCCAATACATCGTCCAAGTTCTATTCTTTC	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for NLuc-FAK-Y576F+Y577F GATAGTACTTTCTCAAAGCTTCCAAGGAAAATTGCC GCTTTGAAGAAAGTACTATCTTCCATATATCGGGATAATCC	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for PYK2-F435R-NLuc GGAAGGCCGTTTTGGGGAGGTCTATGAAGG CCCCAAAACGGCCTTCCCCAAGAATACGATTCAGG	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for PYK2-E474Q-NLuc GTTTCATGAGCCAGGCAGTGATCATGAAGAACC CACTGCCTGGCTCATGAACTTCTCCTTGTGTC	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for PYK2-F435Q-NLuc GGAAGGCCAGTTTGGGGAGGTCTATGAAGG CCCCAAACTGGCCTTCCCCAAGAATACGATTCAGG	Eurofins	https://www.eurofins.com/
Mutagenesis primer pair for PYK2-Y579F+Y580F-NLuc GACGAGGACTTCTCAAAGCCTCTGTGACTCGTCTCC GAGGCTTTGAAGAAGTCTCGTCTCAATGTACCGGG	Eurofins	https://www.eurofins.com/